[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 570
1. Rozenchan PB, Carraro DM, Brentani H, de Carvalho Mota LD, Bastos EP, e Ferreira EN, Torres CH, Katayama ML, Roela RA, Lyra EC, Soares FA, Folgueira MA, Góes JC, Brentani MM: Reciprocal changes in gene expression profiles of cocultured breast epithelial cells and primary fibroblasts. Int J Cancer; 2009 Dec 15;125(12):2767-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reciprocal changes in gene expression profiles of cocultured breast epithelial cells and primary fibroblasts.
  • The importance of epithelial-stroma interaction in normal breast development and tumor progression has been recognized.
  • To identify genes that were regulated by these reciprocal interactions, we cocultured a nonmalignant (MCF10A) and a breast cancer derived (MDA-MB231) basal cell lines, with fibroblasts isolated from breast benign-disease adjacent tissues (NAF) or with carcinoma-associated fibroblasts (CAF), in a transwell system.
  • Our data indicate that interactions between breast fibroblasts and basal epithelial cells resulted in alterations in the genomic profiles of both cell types which may help to clarify some aspects of this heterotypic signaling.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Epithelial Cells / metabolism. Fibroblasts / metabolism. Gene Expression Profiling. Neoplasm Proteins / genetics
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Blotting, Western. Breast / cytology. Cell Proliferation. Coculture Techniques. Female. Gene Expression Regulation, Neoplastic. Humans. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 UICC.
  • (PMID = 19530251.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


2. Zervoudis S, Peitsidis P, Iatrakis G, Panourgias E, Koureas A, Navrozoglou I, Dubois JB: Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results. J BUON; 2007 Oct-Dec;12(4):487-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results.
  • PURPOSE: To analyze, study and interpret the increased levels of tumor markers in breast cancer patients without recurrence or metastasis.
  • PATIENTS AND METHODS: We studied a series of 400 patients with stage 1 breast cancer during a 3-year follow-up after primary treatment.
  • Follow-up included frequent serum estimation of CEA, CA 15.3, CA 125, CA 27-29, TPA and TPS tumor markers.
  • RESULTS: Of 358 patients being continuously disease-free, 18 (5%) cases showed false-positive levels of tumor markers, associated with benign conditions and not to cancer recurrence or metastasis.
  • CONCLUSION: The value of increased tumor markers should be interpreted cautiously because it doesn't always imply disease recurrence.
  • Tumor markers may increase in many benign conditions.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] False Positive Reactions. Female. Follow-Up Studies. Humans. Neoplasm Metastasis. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067207.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


3. Ye YB, Zhou ZF, Chen Q, Li JY, Chen X, Huang WW: [The roles of soluble MICA in immune escape of breast tumor]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Sep;24(9):904-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The roles of soluble MICA in immune escape of breast tumor].
  • AIM: To determine the expression of soluble MICA (sMICA) in serum of patients with breast tumor, and explore the roles of sMICA in immune escape.
  • The cytotoxicity of NK cells to breast cancer cells was observed with MTT assay.
  • RESULTS: sMICA was not detected in the serum of healthy person, but(76.8+/-22.3) ng/L in breast benign tumor patients and (205.4+/-71.3) ng/L in breast malignant tumor patients.
  • There was positive correlation between sMICA levels and breast cancer stage.
  • IL-15 up-regulated the expression of NKG2D on NK cells and increased NK cells cytotoxicity to breast cancer cells.
  • CONCLUSION: sMICA level is positive correlated with breast cancer TNM stage. sMICA reduced the expression of NKG2D, impaired NK-mediated immune surveillance and led to immune escape of breast tumor.
  • [MeSH-major] Breast Neoplasms / blood. Breast Neoplasms / immunology. Histocompatibility Antigens Class I / blood
  • [MeSH-minor] Cells, Cultured. Cytotoxicity, Immunologic. Female. Humans. Killer Cells, Natural / immunology. Neoplasm Staging. Solubility

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18782524.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / MHC class I-related chain A
  •  go-up   go-down


Advertisement
4. Zafrakas M, Losen I, Knüchel R, Dahl E: Enhancer of the rudimentary gene homologue (ERH) expression pattern in sporadic human breast cancer and normal breast tissue. BMC Cancer; 2008;8:145
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancer of the rudimentary gene homologue (ERH) expression pattern in sporadic human breast cancer and normal breast tissue.
  • BACKGROUND: The human gene ERH (Enhancer of the Rudimentary gene Homologue) has previously been identified by in silico analysis of four million ESTs as a gene differentially expressed in breast cancer.
  • The aim of the present study was a systematic characterization of ERH expression in human breast cancer in order to evaluate possible clinical applications of this molecule.
  • METHODS: The expression pattern of ERH was analyzed using multiple tissue northern blots (MTN) on a panel of 16 normal human tissues and two sets of malignant/normal breast and ovarian tissue samples.
  • ERH expression was further analyzed in breast cancer and normal breast tissues and in tumorigenic as well as non-tumorigenic breast cancer cell lines, using quantitative RT-PCR and non-radioisotopic in situ hybridization (ISH).
  • In the two MTN sets of malignant/normal breast and ovarian tissue,ERH was clearly more abundantly expressed in all tumours than in normal tissue samples.
  • Quantitative RT-PCR analyses showed that ERH expression was significantly more abundant in tumorigenic than in non-tumorigenic breast cancer cell lines (4.5-fold; p = 0.05, two-tailed Mann-Whitney U-test); the same trend was noted in a set of 25 primary invasive breast cancers and 16 normal breast tissue samples (2.5-fold; p = 0.1).
  • These findings were further confirmed by non-radioisotopic ISH in human breast cancer and normal breast tissue.
  • CONCLUSION: ERH expression is clearly up-regulated in malignant as compared with benign breast cells both in primary human breast cancer and in cell models of breast cancer.
  • Further studies on large breast cancer tissue cohorts should determine whether ERH could function as a prognostic factor or even a drug target in the treatment of human breast cancer.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Breast / metabolism. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Cell Cycle Proteins / biosynthesis. Gene Expression Regulation, Neoplastic / physiology. Neoplasm Proteins / biosynthesis. Transcription Factors / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Chem. 2001 Sep;382(9):1379-85 [11688721.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):266-73 [17698176.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):641-9 [15289865.001]
  • [Cites] Genetics. 1994 Dec;138(4):1163-70 [7896098.001]
  • [Cites] Genomics. 1996 Feb 15;32(1):125-7 [8786099.001]
  • [Cites] Gene. 1997 Feb 28;186(2):189-95 [9074495.001]
  • [Cites] Nucleic Acids Res. 1999 Nov 1;27(21):4251-60 [10518618.001]
  • [Cites] J Pathol. 2005 Jan;205(1):21-8 [15586368.001]
  • [Cites] FEBS Lett. 2005 Jan 31;579(3):683-9 [15670829.001]
  • [Cites] Biochemistry. 2005 Apr 5;44(13):5017-23 [15794639.001]
  • [Cites] FEBS J. 2008 Jan;275(2):332-40 [18081865.001]
  • [Cites] Oncogene. 2008 Jan 31;27(6):865-76 [17653090.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1453-9 [16187283.001]
  • [Cites] Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 May 1;61(Pt 5):531-3 [16511088.001]
  • [Cites] FEBS J. 2006 Oct;273(20):4728-41 [16984396.001]
  • [Cites] Mol Cell. 2003 Apr;11(4):1055-66 [12718890.001]
  • (PMID = 18500978.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / ERH protein, human; 0 / Neoplasm Proteins; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2426700
  •  go-up   go-down


5. Kohler C, Radpour R, Barekati Z, Asadollahi R, Bitzer J, Wight E, Bürki N, Diesch C, Holzgreve W, Zhong XY: Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer; 2009;8:105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors.
  • METHODS: Using multiplex real-time PCR we investigated the levels of ccf nDNA and mtDNA in plasma samples from patients with malignant and benign breast tumors, and from healthy controls.
  • RESULTS: While the levels of ccf nDNA in the cancer group were significantly higher in comparison with the benign tumor group (P < 0.001) and the healthy control group (P < 0.001), the level of ccf mtDNA was found to be significantly lower in the two tumor-groups (benign: P < 0.001; malignant: P = 0.022).
  • The level of ccf nDNA was also associated with tumor-size (<2 cm vs. >2 cm<5 cm; 2250 vs. 6658; Mann-Whitney-U-Test: P = 0.034).
  • Using ROC curve analysis, we were able to distinguish between the breast cancer cases and the healthy controls using ccf nDNA as marker (cut-off: 1866 GE/ml; sensitivity: 81%; specificity: 69%; P < 0.001) and between the tumor group and the healthy controls using ccf mtDNA as marker (cut-off: 463282 GE/ml; sensitivity: 53%; specificity: 87%; P < 0.001).
  • CONCLUSION: Our data suggests that nuclear and mitochondrial ccf DNA have potential as biomarkers in breast tumor management.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Cell Nucleus / genetics. DNA, Mitochondrial / blood
  • [MeSH-minor] Case-Control Studies. Cell-Free System. Cohort Studies. Diagnosis, Differential. Female. Health. Humans. Lymph Nodes / pathology. Neoplasm Metastasis. ROC Curve. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2006 Aug;24(8):905-8 [16900126.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):629-38 [16568452.001]
  • [Cites] BMC Cancer. 2006;6:269 [17116247.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2631-9 [17182988.001]
  • [Cites] Mitochondrion. 2007 Feb-Apr;7(1-2):157-63 [17280876.001]
  • [Cites] Mitochondrion. 2007 Feb-Apr;7(1-2):53-7 [17320491.001]
  • [Cites] Acta Paediatr. 2007 May;96(5):644-7 [17376185.001]
  • [Cites] Int J Biol Markers. 2007 Apr-Jun;22(2):95-9 [17549664.001]
  • [Cites] Arch Gynecol Obstet. 2007 Oct;276(4):327-31 [17431649.001]
  • [Cites] Prostate. 2008 Mar 1;68(4):408-17 [18196528.001]
  • [Cites] Clin Chem Lab Med. 2008;46(3):311-7 [18254709.001]
  • [Cites] JAMA. 2008 May 14;299(18):2151-63 [18477782.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2A):921-5 [18507037.001]
  • [Cites] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Jun;16(3):699-703 [18549658.001]
  • [Cites] Int J Biol Markers. 2008 Apr-Jun;23(2):69-73 [18629778.001]
  • [Cites] DNA Cell Biol. 2008 Aug;27(8):415-21 [18694299.001]
  • [Cites] Nat Med. 2008 Sep;14(9):985-90 [18670422.001]
  • [Cites] Obstet Gynecol. 2008 Oct;112(4):843-50 [18827127.001]
  • [Cites] Ann N Y Acad Sci. 2008 Aug;1137:175-9 [18837944.001]
  • [Cites] Cytokine. 2008 Oct;44(1):65-9 [18691902.001]
  • [Cites] Expert Rev Neurother. 2008 Dec;8(12):1841-52 [19086880.001]
  • [Cites] Neuroimage. 2009 Jun;46(2):394-410 [19236926.001]
  • [Cites] Clin Chem. 2000 Dec;46(12):1903-6 [11106320.001]
  • [Cites] Lancet. 2001 Jan 27;357(9252):310-1 [11214156.001]
  • [Cites] Swiss Med Wkly. 2001 Feb 10;131(5-6):70-4 [11383228.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;945:138-40 [11708467.001]
  • [Cites] Clin Chim Acta. 2002 Jul;321(1-2):77-87 [12031596.001]
  • [Cites] Int J Gynaecol Obstet. 1995 Feb;48(2):187-92 [7540567.001]
  • [Cites] Lab Invest. 1996 Mar;74(3):592-9 [8600309.001]
  • [Cites] Brain Res Mol Brain Res. 1997 Dec 15;52(2):284-9 [9495550.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):920-4 [15856456.001]
  • [Cites] Tumour Biol. 2005 Nov-Dec;26(6):281-93 [16254457.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1564-9 [16533782.001]
  • [Cites] Prenat Diagn. 2006 Apr;26(4):362-8 [16566058.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1087-91 [17047655.001]
  • (PMID = 19922604.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Mitochondrial; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2780981
  •  go-up   go-down


6. Ozumba BC, Nzegwu MA, Anyikam A, Okoye I, Okafor OC: Breast disease in children and adolescents in eastern Nigeria--a five-year study. J Pediatr Adolesc Gynecol; 2009 Jun;22(3):169-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast disease in children and adolescents in eastern Nigeria--a five-year study.
  • (1) To define the spectrum of breast diseases in the children and adolescents in Eastern Nigeria. (2) To provide where possible, an international comparison of statistical variations of both benign and malignant lesions in these age groups.
  • Virtually all children and adolescents (4-19) years who complained of a breast mass had a biopsy, and results of all excised breast specimens from children and adolescent age groups from 4 to 19 years were included in the study.
  • The case files of these patients were retrieved and reviewed to ascertain the size and duration of the breast lesions.
  • RESULTS: A total of 1050 breast specimens were received in the department of morbid anatomy from all age groups, from January 1, 2000 to December 31, 2004, out of which 121 (11.5%) were breast specimens from the children and adolescent age groups.
  • On the average most patients with benign breast lesions presented within 3-5 months of their symptoms, which usually was a palpable lump detected in all cases by either the child or the mother.
  • Their sizes vary from 2-3 cm and only ten were multiple but they were all confined to one breast.
  • Phyllodes tumor in this age group constitute 28.6% of all phyllodes seen in this period and were all benign.
  • CONCLUSION: Fibro adenoma, fibrocystic breast disease, and low grade phyllodes tumor were the most common breast lesions seen in our children and adolescent population.
  • [MeSH-major] African Continental Ancestry Group / statistics & numerical data. Breast Diseases / ethnology. Breast Diseases / pathology
  • [MeSH-minor] Adolescent. Age Distribution. Child. Child, Preschool. Female. Humans. Incidence. Neoplasm Invasiveness. Nigeria / epidemiology. Prevalence. Retrospective Studies. Risk Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19539203.001).
  • [ISSN] 1873-4332
  • [Journal-full-title] Journal of pediatric and adolescent gynecology
  • [ISO-abbreviation] J Pediatr Adolesc Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Balasenthil S, Broaddus RR, Kumar R: Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. Hum Pathol; 2006 Jun;37(6):656-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas.
  • Endometrial carcinoma is one of the most common malignancies of the female genital tract.
  • Metastasis-associated protein 1 (MTA1) is a component of the Mi-2/nucleosome remodeling and deacetylating complex and acts as a potent corepressor of estrogen receptor in breast cancer cells.
  • We investigated the expression profile of MTA1 in different stages of benign endometrium as well as in endometrial endometrioid adenocarcinoma using immunohistochemistry and Western blotting.
  • Western blot analysis of 6 tumor specimens showed increased expression of MTA1 in all the tumors analyzed.
  • Immunohistochemical staining performed on tumor microarray containing 70 endometrial endometrioid adenocarcinomas of various grades showed increased expression of MTA1 in 53 (75.7%) tumors.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Nucleus / metabolism. Cytoplasm / metabolism. Female. Humans. Immunohistochemistry. Neoplasm Staging

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733204.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 098823
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Repressor Proteins; EC 3.5.1.- / Mta1 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


8. Lorenzen J, Wedel AK, Lisboa BW, Löning T, Adam G: [Diagnostic mammography and sonography: concordance of the breast imaging reporting assessments and final clinical outcome]. Rofo; 2005 Nov;177(11):1545-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic mammography and sonography: concordance of the breast imaging reporting assessments and final clinical outcome].
  • Final clinical outcome (Histology: 554; follow-up: 78) was ascertained in each case and concordance of BI-RADS-categories for mammography and sonography and final diagnosis were analysed.
  • RESULTS: Final diagnosis yielded 230 benign lesions (36 %) and 402 cancers (64 %).
  • [MeSH-major] Breast Neoplasms / radiography. Breast Neoplasms / ultrasonography. Mammography. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Breast / pathology. Data Interpretation, Statistical. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Outcome and Process Assessment (Health Care). Quality Assurance, Health Care. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16302136.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Königsberg R, Rögelsperger O, Jäger W, Thalhammer T, Klimpfinger M, De Santis M, Hudec M, Dittrich C: Cell cycle dysregulation influences survival in high risk breast cancer patients. Cancer Invest; 2008 Aug;26(7):734-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle dysregulation influences survival in high risk breast cancer patients.
  • Recent immunohistological studies suggested that dysregulation of cyclin A, cyclin D, cyclin E, p16(ink4), p21(waf1/cip1), and p27(kip1) are of prognostic value in patients with breast cancer.
  • Our study represents the first comprehensive immunohistochemical cell cycle marker analysis for cdc25A, cyclin A, cyclin D, cyclin E, p16(ink4), p21(waf1/cip1), p27(kip1), and pRb in tumor tissue and adjacent benign breast tissue from 69 primarily untreated breast cancer patients.
  • RESULTS: Sixty-nine patients with untreated, invasive breast cancer (n = 69) were divided into a low/ intermediate and a high risk group according to the St. Gallen 2005 consensus conference.
  • A subgroup of high risk breast cancer patients characterized in addition by overexpression of cdc25A, cyclin A, cyclin E, p16(ink4a), and p27(kip1) experienced a shortened mean survival of 222.03, 235.71, 257.25, 239.18, and 261.94 weeks, respectively.
  • Regarding benign breast tissue adjacent to breast cancer tissue, 59.4% of the patients investigated overexpressed cdc25A, 23.2% overexpressed pRb, and 63.2% exerted dysregulation of p27(kip1) while they proved to be negative for immunohistochemical staining regarding all other markers tested.
  • CONCLUSION: The immunohistological analyses of cdc25A, cyclin A, cyclin E, p16(ink4a), and p27(kip1) have the potential for further refining the risk assessment in patients with untreated breast cancer who belong to the high risk category defined according to the St. Gallen 2005 consensus conference.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. Breast Neoplasms / mortality. Cell Cycle. Cell Cycle Proteins / analysis. Cell Proliferation
  • [MeSH-minor] Adult. Cyclin A / analysis. Cyclin D. Cyclin E / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Cyclin-Dependent Kinase Inhibitor p27. Cyclins / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Intracellular Signaling Peptides and Proteins / analysis. Kaplan-Meier Estimate. Neoplasm Invasiveness. Proportional Hazards Models. Retinoblastoma Protein / analysis. Retrospective Studies. Risk Assessment. Treatment Outcome. cdc25 Phosphatases / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665474.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / CDKN1B protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin A; 0 / Cyclin D; 0 / Cyclin E; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Retinoblastoma Protein; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 3.1.3.48 / CDC25A protein, human; EC 3.1.3.48 / cdc25 Phosphatases
  •  go-up   go-down


10. Eroğlu A, Sari A: Expression of c-kit proto-oncogene product in breast cancer tissues. Med Oncol; 2007;24(2):169-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of c-kit proto-oncogene product in breast cancer tissues.
  • BACKGROUND: The published results on expression of c-kit in benign and malignant breast tissues vary.
  • MATERIALS AND METHODS: The immunohistochemical expression of c-kit proto-oncogene product in 52 invasive breast cancer tissues and 16 benign breast tumor (fibroadenoma) tissues was studied using anti-c-kit proto-oncogene product antibody.
  • RESULTS: In breast cancer tissues, the mean IRS of c-kit proto-oncogene product expression was significantly increased compared to those of fibroadenoma (3.4 +/- 2 and 2.19 +/- 1.8, respectively,p = 0.035).
  • The mean IRS of c-kit expression was higher in the group comprising estrogen (ER) positive tumor than in the group of ER negative (4.1 +/- 2.1 and 2.7 +/- 1.8, respectively,p = 0.012) but no statistically significant relationship was seen between the expression of c-kit proto-oncogene product and other clinicopathological parameters of breast cancer, including histologic type, tumor size, lymph node metastasis, distant metastasis, stage, progesterone receptor, c-erbB-2 expression, menopausal status and age of the patient (p > 0.05).
  • CONCLUSIONS: Our results show that a high level of c-kit expression occurs frequently in invasive breast cancer, and its expression is associated with ER but unrelated to other clinico-pathological variables.
  • [MeSH-major] Breast Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast J. 2004 Jul-Aug;10(4):323-7 [15239791.001]
  • [Cites] Cancer Res. 1992 Nov 15;52(22):6139-43 [1384954.001]
  • [Cites] Clin Exp Metastasis. 2003;20(7):593-7 [14669790.001]
  • [Cites] Am J Clin Pathol. 2005 Nov;124(5):733-9 [16203286.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 May;128(5):239-46 [12029439.001]
  • [Cites] Cell. 1990 Oct 5;63(1):225-33 [1698557.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Br J Cancer. 1996 May;73(10):1233-6 [8630284.001]
  • [Cites] Leuk Lymphoma. 1998 Aug;30(5-6):459-66 [9711908.001]
  • [Cites] EMBO J. 1987 Nov;6(11):3341-51 [2448137.001]
  • [Cites] J Pathol. 2003 Oct;201(2):278-87 [14517845.001]
  • [Cites] Pathologe. 1987 May;8(3):138-40 [3303008.001]
  • [Cites] J Histochem Cytochem. 1994 Nov;42(11):1417-25 [7523489.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Oncologist. 2001;6(3):233-8 [11423669.001]
  • [Cites] Int J Cancer. 1992 Nov 11;52(5):713-7 [1385336.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):188-93 [11865845.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):178-83 [14734467.001]
  • [Cites] Cancer Sci. 2005 Jun;96(6):333-9 [15958055.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):791-5 [10702394.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1277-82 [15846389.001]
  • [Cites] Cell Growth Differ. 1995 Jun;6(6):769-79 [7545433.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):411-4 [12017324.001]
  • [Cites] Am J Pathol. 1993 Jan;142(1):339-46 [7678721.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jan;83(1):33-42 [14997053.001]
  • [Cites] Virchows Arch. 1994;424(2):135-41 [7514077.001]
  • [Cites] Cancer Res. 1991 Apr 1;51(7):1811-6 [1706218.001]
  • (PMID = 17848740.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


11. Schiffhauer LM, Boger JN, Bonfiglio TA, Zavislan JM, Zuley M, Fox CA: Confocal microscopy of unfixed breast needle core biopsies: a comparison to fixed and stained sections. BMC Cancer; 2009;9:265
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confocal microscopy of unfixed breast needle core biopsies: a comparison to fixed and stained sections.
  • BACKGROUND: Needle core biopsy, often in conjunction with ultrasonic or stereotactic guided techniques, is frequently used to diagnose breast carcinoma in women.
  • This paper reports the progress in developing techniques to rapidly screen needle core breast biopsy and surgical specimens at the point of care.
  • CSLM requires minimal tissue processing and has the potential to reduce the time from excision to diagnosis.
  • METHODS: Needle core breast specimens from 49 patients were imaged at the time of biopsy.
  • These lesions had been characterized under the Breast Imaging Reporting And Data System (BI-RADS) as category 3, 4 or 5.
  • Immediately following imaging, the specimens were fixed in buffered formalin and submitted for histological processing and pathological diagnosis.
  • RESULTS: The pathologic diagnoses by standard histology were 7 invasive ductal carcinomas, 2 invasive lobular carcinomas, 3 ductal carcinomas in-situ (CIS), 21 fibrocystic changes/proliferative conditions, 9 fibroadenomas, and 5 other/benign; two were excluded due to imaging difficulties.
  • Morphologic and cellular features of benign and cancerous lesions were identified in the confocal images and were comparable to standard histologic sections of the same tissue.
  • Morphologic and cellular features of benign and cancerous lesions were identified in the confocal images.
  • Additional studies are needed to 1.) establish correlation of the confocal and traditional histologic images for the various diseases of the breast; 2.) validate diagnostic use of CSLM and; 3.) further define features of borderline lesions such as well-differentiated ductal CIS vs. atypical hyperplasia.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Microscopy, Confocal / methods
  • [MeSH-minor] Biopsy. Cell Proliferation. Contrast Media / pharmacology. Female. Humans. Medical Oncology / methods. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2002 Oct;33(10):975-82 [12395369.001]
  • [Cites] Pancreatology. 2001;1(1):48-57 [12120268.001]
  • [Cites] J Invest Dermatol. 2001 Nov;117(5):1137-43 [11710924.001]
  • [Cites] Surgery. 2000 Dec;128(6):1088-1100; discussion 1100-1 [11114647.001]
  • [Cites] BMC Cancer. 2008;8:21 [18215290.001]
  • [Cites] J Biomed Opt. 2008 Sep-Oct;13(5):054001 [19021381.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):051602 [16292950.001]
  • [Cites] J Invest Dermatol. 1999 Sep;113(3):293-303 [10469324.001]
  • [Cites] Clin Dermatol. 2003 Sep-Oct;21(5):359-69 [14678715.001]
  • [Cites] Dermatol Surg. 2003 Aug;29(8):839-46 [12859385.001]
  • [Cites] J Biomed Opt. 2007 Sep-Oct;12(5):051901 [17994884.001]
  • (PMID = 19650910.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ PMC3087331
  •  go-up   go-down


12. Corben AD, Nehhozina T, Garg K, Vallejo CE, Brogi E: Endosalpingiosis in axillary lymph nodes: a possible pitfall in the staging of patients with breast carcinoma. Am J Surg Pathol; 2010 Aug;34(8):1211-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endosalpingiosis in axillary lymph nodes: a possible pitfall in the staging of patients with breast carcinoma.
  • The occurrence of benign epithelial inclusions in lymph nodes is well documented and can sometimes mimic metastatic carcinoma.
  • Benign müllerian inclusions, such as endometriosis and endosalpingiosis, are common in pelvic and para-aortic lymph nodes, but their presence in supradiaphragmatic lymph nodes is a rare event.
  • We report our experience with 3 patients found to have endosalpingiosis in axillary sentinel lymph nodes obtained for staging of breast carcinoma.
  • Endosalpingiosis had been misinterpreted as metastatic carcinoma at another hospital in 1 of the 3 patients, with subsequent dissection of 19 additional benign axillary lymph nodes.
  • Morphologic identification of ciliated cells and "peg" cells is most helpful to recognize this benign inclusion, and positive immunoreactivity for WT1 and/or PAX8 can be used to support the diagnosis.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Diagnostic Errors / prevention & control. Epithelial Cells / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cilia. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Neoplasm Staging. Paired Box Transcription Factors / analysis. Predictive Value of Tests. Sentinel Lymph Node Biopsy. Unnecessary Procedures. WT1 Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20631604.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors; 0 / WT1 Proteins
  • [Number-of-references] 32
  •  go-up   go-down


13. Chung A, Yu J, Stempel M, Patil S, Cody H, Montgomery L: Is the "10% rule" equally valid for all subsets of sentinel-node-positive breast cancer patients? Ann Surg Oncol; 2008 Oct;15(10):2728-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is the "10% rule" equally valid for all subsets of sentinel-node-positive breast cancer patients?
  • BACKGROUND: In breast cancer, a combination of radioisotope and blue dye mapping maximizes the success and accuracy of sentinel node (SLN) biopsy.
  • METHODS: Between 9/96 and 12/04, we performed 6,369 successful SLN biopsies using (99m)Tc sulfur colloid and isosulfan blue dye, removing as SLN all radioactive and/or blue nodes, and taking counts from each node ex vivo.
  • Standard processing of all SLNs with a benign frozen section included hematoxylin and eosin (H&E) staining, serial sectioning, and immunohistochemistry (IHC).
  • The most radioactive SLN was benign in 29% (398/1,387), and 107/1,387 (8%) had a positive SLN that was neither blue nor the hottest.
  • [MeSH-major] Breast Neoplasms / pathology. Lymph Node Excision. Lymph Nodes / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Intraductal, Noninfiltrating / radionuclide imaging. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Lobular / radionuclide imaging. Carcinoma, Lobular / secondary. Coloring Agents. Female. Humans. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Prospective Studies. Radiopharmaceuticals. Retrospective Studies. Rosaniline Dyes. Sentinel Lymph Node Biopsy. Technetium Tc 99m Sulfur Colloid

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Isosulfan blue .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688679.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Radiopharmaceuticals; 0 / Rosaniline Dyes; 39N9K8S2A4 / iso-sulfan blue; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
  •  go-up   go-down


14. Jaremko M, Justenhoven C, Abraham BK, Schroth W, Fritz P, Brod S, Vollmert C, Illig T, Brauch H: MALDI-TOF MS and TaqMan assisted SNP genotyping of DNA isolated from formalin-fixed and paraffin-embedded tissues (FFPET). Hum Mutat; 2005 Mar;25(3):232-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We isolated constitutional DNA from 274 FFPET samples (229 patients with breast cancer and 45 patients with benign breast diseases) and genotyped 15 polymorphic loci in 10 genes.
  • Furthermore, genotype frequencies matched those observed in a German breast cancer population and other Caucasian populations.
  • [MeSH-minor] Alleles. Breast Diseases / genetics. Breast Diseases / pathology. Breast Neoplasms / genetics. Breast Neoplasms / pathology. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Female. Formaldehyde. Genotype. Humans. Neoplasm Proteins / genetics. Paraffin Embedding. Taq Polymerase

  • Biospecimen Research Database. Biospecimen Research Database .
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15706592.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 1HG84L3525 / Formaldehyde; 9007-49-2 / DNA; EC 2.7.7.- / Taq Polymerase
  •  go-up   go-down


15. Tse GM, Niu Y, Shi HJ: Phyllodes tumor of the breast: an update. Breast Cancer; 2010;17(1):29-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumor of the breast: an update.
  • Phyllodes tumor is an uncommon biphasic breast tumor, with the ability to recur and metastasize, and it behaves biologically like a stromal neoplasm.
  • Traditionally, phyllodes tumors are graded by the use of a set of histologic data into benign, borderline, and malignant.
  • The expression of many biological markers, including p53, hormone receptors, proliferation markers, angiogenesis group of markers, c-kit, CD10 and epidermal growth factor receptor have been explored, and many have been shown to be variably expressed, depending on the grade of the tumor.
  • These markers are, however, of limited value in predicting the behavior of the tumor.
  • It is foreseeable that more exciting data will be generated to help us to understand the etiology and pathogenesis of phyllodes tumor.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / pathology. Phyllodes Tumor / pathology
  • [MeSH-minor] Female. Humans. Neoplasm Staging. Prognosis


16. Kelly RJ, Barrett C, Swan N, McDermott R: Metastatic phyllodes tumor causing small-bowel obstruction. Clin Breast Cancer; 2009 Aug;9(3):193-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic phyllodes tumor causing small-bowel obstruction.
  • Cystosarcoma phyllodes is an important but relatively uncommon fibroepithelial breast neoplasm that accounts for 0.5%-1.0% of female breast carcinomas.
  • This report highlights a unique case of a metastatic phyllodes breast tumor leading to small bowel obstruction.
  • Phyllodes tumors are generally classified into histologic subtypes of benign, intermediate, and malignant, using agreed classification systems.
  • The tumor characteristics that can lead to the dedifferentiation of a relatively benign phenotype to an overt malignant process are discussed.
  • [MeSH-major] Breast Neoplasms / pathology. Ileal Neoplasms / secondary. Intestinal Obstruction / etiology. Phyllodes Tumor / pathology
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Mastectomy. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661046.001).
  • [ISSN] 1938-0666
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


17. Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR: Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol; 2010;8:147
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recent data provide significant evidence to support the hypothesis that there are sub-populations of cells within solid tumors that have an increased tumor initiating potential relative to the total tumor population.
  • CD133, a cell surface marker expressed on primitive cells of neural, hematopoietic, endothelial and epithelial lineages has been identified as a marker for tumor initiating cells in solid tumors of the brain, colon, pancreas, ovary and endometrium.
  • In addition, we confirmed the tumor initiating potential of CD133+ and CD133- cell fractions in NOD/SCID mice.
  • Interestingly, the percentage of CD133+ cells in human endometrial tumor xenografts, as evidenced by immunofluorescence, increased with serial transplantation although this trend was not consistently detected by flow cytometry.
  • To support this finding, we demonstrated that regions of the CD133 promoter were hypomethylated in malignant endometrial tissue relative to benign control endometrial tissue.
  • Lastly, we determined that methylation of the CD133 promoter decreases over serial transplantation of an endometrial tumor xenograft.
  • [MeSH-minor] Animals. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Female. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Res. 2008 Oct;18(10):1037-46 [18679414.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8094-103 [18829568.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Cancer Lett. 2009 Jun 28;279(1):13-21 [19232461.001]
  • [Cites] Biol Reprod. 2009 Jun;80(6):1136-45 [19228591.001]
  • [Cites] Anticancer Res. 2009 Jun;29(6):2235-7 [19528487.001]
  • [Cites] Clin Cancer Res. 2009 Jul 1;15(13):4299-311 [19509143.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] BMC Cancer. 2009;9:221 [19583859.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8241-8 [19843861.001]
  • [Cites] Stem Cells. 2009 Oct;27(10):2405-13 [19658191.001]
  • [Cites] Stem Cells. 2009 Dec;27(12):2875-83 [19816957.001]
  • [Cites] J Biochem. 2010 Sep;148(3):273-80 [20551139.001]
  • [Cites] Hum Pathol. 2010 Nov;41(11):1516-29 [20800872.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):213-23 [14747944.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] Endocr Relat Cancer. 2000 Dec;7(4):227-42 [11174845.001]
  • [Cites] Breast Cancer Res. 2003;5(1):R1-8 [12559051.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2055-61 [14630820.001]
  • [Cites] Biol Reprod. 2004 Jun;70(6):1738-50 [14766732.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Biol Reprod. 1989 Mar;40(3):681-90 [2758097.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5002-12 [9389720.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5013-21 [9389721.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1529-38 [16456137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Hum Reprod. 2007 Jan;22(1):45-51 [16923745.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Hum Reprod. 2007 May;22(5):1214-23 [17283036.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):479-85 [17762575.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):242-9 [18256549.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):506-14 [17868344.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] J Mol Med (Berl). 2008 Sep;86(9):1025-32 [18535813.001]
  • [Cites] Oncogene. 2009 Jan 15;28(2):209-18 [18836486.001]
  • (PMID = 21122138.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC3027593
  •  go-up   go-down


18. De Vries J, Van der Steeg AF, Roukema JA: Trait anxiety determines depressive symptoms and fatigue in women with an abnormality in the breast. Br J Health Psychol; 2009 Feb;14(Pt 1):143-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trait anxiety determines depressive symptoms and fatigue in women with an abnormality in the breast.
  • OBJECTIVES: The aim was to examine the role of trait anxiety and diagnosis on depressive symptoms and fatigue in women with early stage breast cancer or benign breast problems.
  • METHODS: From the 169 participating women, 81 patients had breast cancer and 88 benign breast problems.
  • Questionnaires for depressive symptoms and fatigue were completed before diagnosis (T1) and 1 (T2), 3 (T3), and 6 (T4) months after diagnosis (benign patients) or surgical treatment (breast cancer patients).
  • A trait anxiety questionnaire was only completed before diagnosis was known.
  • RESULTS: Trait anxiety, assessed before diagnosis, was the only significant predictor of depressive symptoms at T4, even when depressive symptoms at baseline was included in the analysis.
  • Demographic characteristics, diagnosis (benign or breast cancer) and adjuvant treatment (chemotherapy, radiotherapy, hormone therapy) did not play a role.
  • Patients with breast cancer or benign breast problems scoring high on trait anxiety, scored higher on depressive symptoms and fatigue than the other patients, at all time points.
  • [MeSH-major] Anxiety Disorders / epidemiology. Anxiety Disorders / psychology. Breast Neoplasms / epidemiology. Breast Neoplasms / psychology. Depressive Disorder / epidemiology. Depressive Disorder / psychology. Fatigue / epidemiology. Fatigue / psychology
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Neoplasm Staging. Prospective Studies. Severity of Illness Index. Surveys and Questionnaires


19. Grenier J, Delbaldo C, Zelek L, Piedbois P: [Phyllodes tumors and breast sarcomas: a review]. Bull Cancer; 2010 Oct;97(10):1197-207
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phyllodes tumors and breast sarcomas: a review].
  • [Transliterated title] Tumeurs phyllodes et sarcomes du sein: mise au point.
  • Phyllodes tumors and sarcomas of the breast are non-epithelial tumors of the breast.
  • Phyllodes tumors are benign tumors, tumors of intermediate malignancy or malignant tumors.
  • The differential diagnosis with a very proliferant fibroadenoma may be difficult.
  • Radiotherapy is recommended in case of high-grade tumor and after conservativetreatment.
  • Breast sarcomas are even rarer.
  • Grade, involved margins and sometimes tumor necrosis are major prognostics factors.
  • In some situations, a conservative treatment can be discussed, based on tumor size, grade and volume of the breast.
  • [MeSH-major] Breast Neoplasms / pathology. Phyllodes Tumor / pathology. Sarcoma / pathology
  • [MeSH-minor] Female. Hemangiosarcoma / pathology. Hemangiosarcoma / secondary. Hemangiosarcoma / therapy. Humans. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855241.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  •  go-up   go-down


20. Afify A, Purnell P, Nguyen L: Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol; 2009 Apr;86(2):95-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion.
  • The interaction between the transmembrane receptor CD44 on epithelial tumor cells and its ligand hyaluronan in the surrounding extracellular matrix is important in tumor progression and metastasis.
  • Previously, we demonstrated that hyaluronan (HA) production is increased at tumor-stroma interface in invasive and metastatic human breast cancers when compared with benign or premalignant lesions.
  • We hypothesize that CD44 expression on breast cancer cells is a major contributing factor to cell adhesion, migration and invasion.
  • To evaluate this hypothesis we examined the effects of 3 distinct anti-CD44s and 2 anti-CD44v6 monoclonal antibodies on breast cancer cell lines that expressed high and low CD44s and CD44v6.
  • Our results showed that anti-CD44s could inhibit breast cancer cell adhesion, motility and invasion, while anti-CD44v6 inhibits cell motility.
  • In conclusion, our data suggests that CD44s is involved in breast cancer cell adhesion, motility and invasion through interaction with HA but CD44v6 is involved only in cell motility.
  • Furthermore we concluded that antibodies against different epitopes on CD44 mediate distinct functional effects on breast cancer cells.
  • [MeSH-major] Antigens, CD44 / metabolism. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Movement
  • [MeSH-minor] Cell Adhesion. Cell Line, Tumor. Cell Membrane / metabolism. Cell Proliferation. Collagen / metabolism. Drug Combinations. Female. Humans. Hyaluronic Acid / metabolism. Laminin / metabolism. Molecular Weight. Neoplasm Invasiveness. Protein Isoforms / metabolism. Proteoglycans / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19167378.001).
  • [ISSN] 1096-0945
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Drug Combinations; 0 / Laminin; 0 / Protein Isoforms; 0 / Proteoglycans; 119978-18-6 / matrigel; 9004-61-9 / Hyaluronic Acid; 9007-34-5 / Collagen
  •  go-up   go-down


21. Bacci G, Ferrari C, Longhi A, Ferrari S, Forni C, Bacchini P, Palmerini E, Briccoli A, Pignotti E, Balladelli A, Picci P: Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol; 2006 Dec;28(12):774-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy.
  • Twenty-six patients (2.15%) developed a second malignant neoplasm at a median of 7.6 years (1 to 25 y) after primary osteosarcoma treatment.
  • Second neoplasms were leukemia (10), breast (7), lung (2), kidney (2), central nervous system cancer (2), soft tissue (1), parotid (1), and colon (1).
  • The rate of second neoplasms was significantly higher in female patients, and the latent period shorter in hematologic tumors compared with solid tumors.
  • The rate of second malignancies observed in the osteosarcoma group was significantly higher than that observed in the control group of 1160 patients with benign tumors treated in the same period at our Institute (2.2% vs. 0.8%, P<0.009).
  • Our study showed that the risk of second neoplasm within 15 years increased and then leveled off and that although secondary solid tumors could be explained as unrelated cases, leukemias seem to be over represented.
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant / methods. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Incidence. Infant. Male. Neoplasms / drug therapy. Neoplasms / epidemiology. Retrospective Studies. Risk Factors. Sex Factors. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164644.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Choi N, Ko ES: Invasive ductal carcinoma in a mammary hamartoma: case report and review of the literature. Korean J Radiol; 2010 Nov-Dec;11(6):687-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mammary hamartomas are typically a benign condition and rarely develop into malignant lesions.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Hamartoma / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Mammography. Mastectomy, Modified Radical. Neoplasm Invasiveness. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):64-6 [10882247.001]
  • [Cites] Indian J Pathol Microbiol. 2009 Apr-Jun;52(2):249-51 [19332930.001]
  • [Cites] J Clin Pathol. 2002 Jul;55(7):541-2 [12101205.001]
  • [Cites] Clin Radiol. 2003 Jan;58(1):80-3 [12565210.001]
  • [Cites] Breast J. 2003 May-Jun;9(3):246-8 [12752637.001]
  • [Cites] Yonsei Med J. 2003 Oct 30;44(5):847-54 [14584102.001]
  • [Cites] Surg Gynecol Obstet. 1971 Oct;133(4):577-82 [5096305.001]
  • [Cites] Acta Radiol Diagn (Stockh). 1982;23(5):503-5 [7158415.001]
  • [Cites] Radiology. 1989 Feb;170(2):417-21 [2911664.001]
  • [Cites] J Clin Pathol. 1992 Oct;45(10):936-7 [1430271.001]
  • [Cites] Am J Clin Pathol. 1995 Jun;103(6):685-9 [7785651.001]
  • [Cites] Pathol Res Pract. 1996 Dec;192(12):1187-94 [9182287.001]
  • [Cites] Breast J. 2006 Jul-Aug;12(4):368-70 [16848850.001]
  • [Cites] J Ultrasound Med. 2007 Apr;26(4):447-52; quiz 453 [17384041.001]
  • [Cites] J Clin Pathol. 2002 Jan;55(1):76-7 [11825932.001]
  • (PMID = 21076596.001).
  • [ISSN] 2005-8330
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2974232
  • [Keywords] NOTNLM ; Invasive ductal carcinoma / Mammary hamartoma
  •  go-up   go-down


23. Aranda C, Sotelo M, Torres A, Zárate M: [Phyllodes tumor and pregnancy. A report of a case]. Ginecol Obstet Mex; 2005 Jul;73(7):387-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phyllodes tumor and pregnancy. A report of a case].
  • [Transliterated title] Tumor phyllodes y embarazo. Reporte de un caso.
  • Phyllodes tumor is a rare breast fibroepithelial neoplasm of the breast, predominant in females (0.3 to 0.5%).
  • Phyllodes tumor during pregnancy grows fast and its size is relatively big.
  • These tumors can be classified as benign, malignant or neighboring.
  • A 32-year-old patient at 23.4 week of gestation was admitted in the National Institute of Perinatology with a rapidly growing mass in the right breast; diagnosis confirmed by ultrasound study reporting echoic images on right breast, 10 x 10 cm the greatest and 3x3 cm the smallest.
  • A simple mastectomy was performed at the 26.6 week of gestation on the right breast.
  • A possible phyllodes tumour in the right breast was observed during surgery, weight 9.6 pounds, with partial infiltration to major pectoral muscle.
  • Pathology reported a benign phyllodes tumor in the right breast, with surgical borders free of tumor.
  • Phyllodes tumor is rare and can occur during pregnancy.
  • It is unknown if the tumor is hormone-dependent.
  • The growth of a tumor on a subsequent pregnancy is not necessarily associated with recurrency or with a new disorder on the patient, who has had a complete excision.
  • [MeSH-major] Breast Neoplasms. Phyllodes Tumor. Pregnancy Complications, Neoplastic
  • [MeSH-minor] Adult. Female. Humans. Pregnancy


24. Fleming NA, Hopkins L, de Nanassy J, Senterman M, Black AY: Mullerian adenosarcoma of the cervix in a 10-year-old girl: case report and review of the literature. J Pediatr Adolesc Gynecol; 2009 Aug;22(4):e45-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Müllerian adenosarcoma is a rare neoplasm usually found in postmenopausal women.
  • It is a biphasic tumor, composed of a benign epithelial component and a malignant stromal component.
  • To date, this neoplasm has been reported in only 16 adolescent girls.
  • We present a case of a 10-year-old girl who was diagnosed with müllerian adenosarcoma arising from the endocervix, the youngest female ever reported.
  • On physical examination, her vital signs were stable, and pubertal development was Tanner III breast and Tanner II pubic development.
  • Pathology confirmed a diagnosis of müllerian adenosarcoma originating from the endocervix.
  • After a thorough evaluation of the available literature, review with the Regional Tumor Board and extensive discussions with the family, a decision was made to perform a radical hysterectomy, bilateral salpingectomy, bilateral pelvic lymph node dissection, upper vaginectomy and preservation of ovaries.
  • CONCLUSION: Müllerian adenosarcoma of the endocervix is a very rare pediatric tumor.
  • Due to the rarity of this tumor in this age group, optimal therapy is uncertain.
  • [MeSH-minor] Child. Female. Humans


25. Strobel K, Haerle SK, Stoeckli SJ, Schrank M, Soyka JD, Veit-Haibach P, Hany TF: Head and neck squamous cell carcinoma (HNSCC)--detection of synchronous primaries with (18)F-FDG-PET/CT. Eur J Nucl Med Mol Imaging; 2009 Jun;36(6):919-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten second cancers (18%) were located outside the aerodigestive tract (colon, five; stomach, lymphoma, breast, thymus and kidney, one each).
  • False-positive PET/CT findings were mainly related to benign FDG uptake in the intestine due to benign or precancerous polyps or physiological FDG uptake in other head and neck regions.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. False Positive Reactions. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / diagnostic imaging. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / therapy. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1173-8 [14623746.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jun;128(6):703-7 [12049568.001]
  • [Cites] Head Neck. 2002 Apr;24(4):345-9 [11933176.001]
  • [Cites] Neuroradiology. 2008 Nov;50(11):969-79 [18600319.001]
  • [Cites] Radiother Oncol. 2008 May;87(2):221-9 [18410977.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Feb;124(2):208-12 [11226943.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Jul;137(1):130-7 [17599580.001]
  • [Cites] Head Neck. 2007 Nov;29(11):986-95 [17563906.001]
  • [Cites] Head Neck. 1989 Sep-Oct;11(5):426-30 [2807882.001]
  • [Cites] J Nucl Med. 2004 Nov;45(11):1804-10 [15534047.001]
  • [Cites] J Comput Assist Tomogr. 1999 Jul-Aug;23 (4):603-8 [10433294.001]
  • [Cites] Cancer. 1995 Mar 15;75(6):1343-53 [7882285.001]
  • [Cites] Am J Surg. 1987 Oct;154(4):434-8 [3661848.001]
  • [Cites] Nucl Med Commun. 2005 Aug;26(8):671-87 [16000985.001]
  • [Cites] Oral Oncol. 2006 Mar;42(3):275-80 [16266820.001]
  • [Cites] Laryngoscope. 2007 Jul;117(7):1173-9 [17603315.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Sep;17(3):467-76 [2674075.001]
  • [Cites] Laryngoscope. 2003 May;113(5):888-91 [12792328.001]
  • [Cites] Ann Nucl Med. 2006 Nov;20(9):597-604 [17294670.001]
  • [Cites] Oral Oncol. 2003 Sep;39(6):547-51 [12798396.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] Am J Surg. 1964 Oct;108:552-7 [14211447.001]
  • [Cites] AJR Am J Roentgenol. 2004 May;182(5):1129-32 [15100107.001]
  • (PMID = 19205699.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


26. Guo J, Shou C, Meng L, Jiang B, Dong B, Yao L, Xie Y, Zhang J, Chen Y, Budman DR, Shi YE: Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer. Int J Cancer; 2007 Sep 15;121(6):1296-305
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer.
  • Synuclein gamma (SNCG), previously identified as a breast cancer-specific gene (BCSG1), is highly expressed in breast carcinomas but not in normal epithelium.
  • SNCG regulates many pathways in growth and progression of breast cancer.
  • To determine if SNCG is a biomarker for clinical prognosis of breast cancer, we generated a panel of murine monoclonal antibodies (mAbs) against human SNCG and correlated SNCG protein expression in 358 clinical breast cancer specimens with clinical outcome.
  • SNCG protein expression was determined in 438 clinical breast specimens by immunohistochemical analysis using mAb 5C5.
  • Expression of SNCG was strongly correlated with the stage, lymph node involvement, metastasis, tumor size and Her-2 status, but its expression was not associated with ER and PR expression status.
  • While 71.4% of advanced breast cancers were positive for SNCG expression, only 26.8% of Stage I/II breast cancers were positive for SNCG expression and 5.2% of benign hyperplasia expressed SNCG.
  • SNCG protein was not detectable in normal tissue adjacent to breast cancer.
  • After a median follow-up of 64 months, patients with an SNCG-positive tumor had a significantly shorter disease-free survival and overall survival and a high probability of death compared no expression of SNCG.
  • SNCG is a new unfavorable prognostic marker for breast cancer progression and a potential target for breast cancer treatment.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / metabolism. Neoplasm Proteins / metabolism. gamma-Synuclein / metabolism
  • [MeSH-minor] Amino Acid Sequence. Animals. Antibodies, Monoclonal. Blotting, Western. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression. Humans. Immunohistochemistry. Immunoprecipitation. Kaplan-Meier Estimate. Lymphatic Metastasis. Mice. Middle Aged. Molecular Sequence Data. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17534899.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / SNCG protein, human; 0 / gamma-Synuclein
  •  go-up   go-down


27. Kebudi A, Calişkan C, Yetkin G, Celebi S, Işgör A, Mesrur Halefoğlu A, Ezdeşir R, Akgün I: The role of pre-operative B mode ultrasound in the evaluation of the axillary lymph node metastases in the initial staging of breast carcinoma. Acta Chir Belg; 2005 Sep-Oct;105(5):511-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of pre-operative B mode ultrasound in the evaluation of the axillary lymph node metastases in the initial staging of breast carcinoma.
  • The lymph node status of a breast cancer is one of the main prognostic criterias.
  • Mammographic examination can give us an idea about breast cancer and axillary involvement.
  • 42 patients operated on for breast cancer between January 2000-January 2003 were included in this prospective study.
  • Hyperechogenic hilus was accepted as a benign finding.
  • The thickening of the cortex less than 50% of the thickening of the centric echogenic hilus was also accepted as a benign finding.
  • As a result, these lymph nodes were defined as benign in 19 patients (45.2%) and malignant in 23 patients (54.8%).
  • Axillary lymph node status was found as benign in 18 patients (42.9%) and malignant in 24 patients (57.1%) pathologically .
  • We think some better results may be obtained in the future and these developments may affect the surgeon's decisions concerning axillary dissection for breast cancer operations.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Lymphatic Metastasis / ultrasonography. Neoplasm Staging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Axilla. Female. Humans. Middle Aged. Preoperative Care. Sensitivity and Specificity. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315836.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


28. Guttery DS, Hancox RA, Mulligan KT, Hughes S, Lambe SM, Pringle JH, Walker RA, Jones JL, Shaw JA: Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. Breast Cancer Res; 2010;12(4):R57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of invasion-promoting tenascin-C additional domains with breast cancers in young women.
  • The profile of isoforms expressed differs between cancers and normal breast, with the two additional domains AD1 and AD2 considered to be tumour associated.
  • The aim of the present study was to investigate expression of AD1 and AD2 in normal, benign and malignant breast tissue to determine their relationship with tumour characteristics and to perform in vitro functional assays to investigate the role of AD1 in tumour cell invasion and growth.
  • METHODS: Expression of AD1 and AD2 was related to hypoxanthine phosphoribosyltransferase 1 as a housekeeping gene in breast tissue using quantitative RT-PCR, and the results were related to clinicopathological features of the tumours.
  • Constructs overexpressing an AD1-containing isoform (TNC-14/AD1/16) were transiently transfected into breast carcinoma cell lines (MCF-7, T-47 D, ZR-75-1, MDA-MB-231 and GI-101) to assess the effect in vitro on invasion and growth.
  • RESULTS: Quantitative RT-PCR detected AD1 and AD2 mRNA expression in 34.9% and 23.1% of 134 invasive breast carcinomas, respectively.
  • AD1 mRNA was localised by in situ hybridisation to tumour epithelial cells, and more predominantly to myoepithelium around associated normal breast ducts.
  • CONCLUSIONS: Together these data suggest a highly significant association between AD-containing TNC isoforms and breast cancers in younger women (age ≤40 years), which may have important functional significance in vivo.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2000 Jan;105(1):21-34 [10619858.001]
  • [Cites] Br J Cancer. 1996 Dec;74(11):1796-800 [8956795.001]
  • [Cites] Matrix Biol. 2000 Dec;19(7):581-96 [11102748.001]
  • [Cites] Lancet. 2001 Jun 23;357(9273):1992-4 [11438127.001]
  • [Cites] Cell Struct Funct. 2001 Jun;26(3):179-87 [11565810.001]
  • [Cites] Int J Cancer. 2002 Mar 10;98(2):205-9 [11857409.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1152-6 [11948127.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):97-104 [12027581.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3289-97 [12036947.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2362-70 [12460779.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1857-67 [12759243.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):8-16 [12794751.001]
  • [Cites] J Pathol. 2003 Dec;201(4):562-72 [14648659.001]
  • [Cites] Science. 2004 Feb 6;303(5659):775-7 [14764858.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7377-85 [15492259.001]
  • [Cites] N Engl J Med. 1986 Aug 28;315(9):559-63 [3736639.001]
  • [Cites] J Cell Biol. 1991 Nov;115(4):1127-36 [1720121.001]
  • [Cites] J Cell Physiol. 1992 Mar;150(3):534-44 [1537883.001]
  • [Cites] Lancet. 1992 Jun 13;339(8807):1483 [1351156.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5190-7 [1382837.001]
  • [Cites] Int J Cancer. 1992 Nov 11;52(5):688-92 [1385335.001]
  • [Cites] Nucleic Acids Res. 1993 Jan 11;21(1):163-8 [7680113.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1039-43 [8096955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10154-8 [7694284.001]
  • [Cites] Development. 1994 Mar;120(3):637-47 [7512896.001]
  • [Cites] J Cell Biol. 1994 Jul;126(2):539-48 [7518469.001]
  • [Cites] Mol Biol Cell. 1994 Apr;5(4):439-53 [7519905.001]
  • [Cites] FEBS Lett. 1994 Sep 26;352(2):216-8 [7523186.001]
  • [Cites] J Biol Chem. 1995 Apr 14;270(15):8650-4 [7536739.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):97-103 [8630946.001]
  • [Cites] FEBS Lett. 1996 Jul 8;389(3):304-8 [8766721.001]
  • [Cites] Mol Biol Cell. 1996 Jun;7(6):883-92 [8816995.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):999-1004 [8855965.001]
  • [Cites] Int J Cancer. 1997 Jul 17;72(2):236-40 [9219826.001]
  • [Cites] Differentiation. 1997 Nov;62(2):71-82 [9404002.001]
  • [Cites] J Cell Sci. 1998 Apr;111 ( Pt 8):1095-104 [9512505.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1998 Jun;39(7):1135-42 [9620072.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1507-13 [9836485.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1345-52 [10329587.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):477-83 [10404058.001]
  • [Cites] Cell. 1999 Jul 23;98(2):137-46 [10428026.001]
  • [Cites] Mol Biol Cell. 1999 Sep;10(9):2933-43 [10473637.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4003-11 [15930334.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5175-80 [16033833.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3200-8 [16707621.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Histopathology. 2007 Mar;50(4):434-8 [17448018.001]
  • [Cites] Mol Biol Cell. 2007 Nov;18(11):4615-24 [17855508.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):34929-37 [17901052.001]
  • [Cites] Breast Cancer Res. 2007;9(6):404; author reply 405 [18279542.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1368-76 [18316557.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):6942-52 [18757408.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5555-64 [18765548.001]
  • [Cites] Breast Cancer Res. 2009;11(2):R24 [19405959.001]
  • [Cites] J Vis Exp. 2009;(29). pii: 1475. doi: 10.3791/1475 [19620957.001]
  • [Cites] J Pathol. 1999 Dec;189(4):475-80 [10629546.001]
  • (PMID = 20678196.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / Tenascin
  • [Other-IDs] NLM/ PMC2949648
  •  go-up   go-down


29. Gashi-Luci LH, Limani RA, Kurshumliu FI: Invasive ductal carcinoma within fibroadenoma: a case report. Cases J; 2009;2:174
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Fibroadenoma is the most common benign tumor of the female breast with the highest incidence before age 30.
  • CASE PRESENTATION: We present a rare case of a 39 years old female with invasive ductal carcinoma arising within fibroadenoma.
  • CONCLUSION: There is a low percentage of fibroadenomas harboring carcinoma; however, all breast lumps should be seriously managed; extirpation and histological examination is recommended.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Cancer. 2009 Jul-Sep;46(3):244-6 [19574682.001]
  • [Cites] Pathol Int. 1994 Dec;44(12):874-7 [7866572.001]
  • [Cites] N Engl J Med. 1994 Jul 7;331(1):10-5 [8202095.001]
  • [Cites] Am J Clin Pathol. 1991 May;95(5):614-22 [1850948.001]
  • [Cites] Surg Gynecol Obstet. 1985 Feb;160(2):99-104 [2982218.001]
  • [Cites] Can J Surg. 1985 Jul;28(4):372-4 [2990650.001]
  • [Cites] Am J Clin Pathol. 2001 May;115(5):736-42 [11345838.001]
  • [Cites] Major Probl Pathol. 1979;11:i-xvi, 1-466 [547120.001]
  • [Cites] Cancer. 1975 Feb;35(2):450-6 [1111920.001]
  • [Cites] Int J Clin Oncol. 2004 Aug;9(4):334-8 [15375712.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):572-4 [15297206.001]
  • [Cites] J Clin Pathol. 2002 Oct;55(10):795-7 [12354814.001]
  • [Cites] Arch Pathol Lab Med. 1984 Jul;108(7):590-4 [6329129.001]
  • (PMID = 19946485.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2783130
  •  go-up   go-down


30. El-Tanani MK, Jin D, Campbell FC, Johnston PG: Interferon-induced transmembrane 3 binds osteopontin in vitro: expressed in vivo IFITM3 reduced OPN expression. Oncogene; 2010 Feb 4;29(5):752-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inhibition of IFITM3 by antisense RNA promoted OPN protein expression, enhanced cell invasion by parental benign non-invasive Rama 37 cells, indicating that the two proteins interact functionally as well.
  • [MeSH-major] Breast Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Membrane Proteins / metabolism. Osteopontin / metabolism. RNA-Binding Proteins / metabolism
  • [MeSH-minor] Animals. Blotting, Northern. Blotting, Western. Cell Adhesion / physiology. Cell Line, Tumor. Cell Movement / physiology. Female. Humans. Immunoprecipitation. Neoplasm Invasiveness / genetics. Promoter Regions, Genetic. RNA, Messenger / analysis. Rats

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19901966.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / IFITM3 protein, human; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 106441-73-0 / Osteopontin
  •  go-up   go-down


31. Karim RZ, Gerega SK, Yang YH, Horvath L, Spillane A, Carmalt H, Scolyer RA, Lee CS: Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours. J Clin Pathol; 2009 Nov;62(11):1016-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 65 PTs (34 benign, 23 borderline and 8 malignant) diagnosed at a single institution between 1990 and 2006 were analysed.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Phyllodes Tumor / metabolism. Wnt Proteins / metabolism
  • [MeSH-minor] Cadherins / metabolism. Cohort Studies. Disease Progression. Female. Humans. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins / metabolism. Signal Transduction / physiology. Survival Analysis. Tissue Array Analysis / methods. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861560.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; 0 / SFRP4 protein, human; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


32. Ichihara S, Ikeda T, Kimura K, Hanatate F, Yamada F, Hasegawa M, Moritani S, Yatabe Y: Coincidence of mammary and sentinel lymph node papilloma. Am J Surg Pathol; 2008 May;32(5):784-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 47-year-old Japanese female underwent 5 needle manipulations and 2 surgical biopsies for recurring papillomas in the right breast over 5 years before having a simple mastectomy.
  • During the mastectomy, the ipsilateral sentinel node was found to be extensively occupied by completely benign papilloma that measured 6 mm in its greatest dimension.
  • The presence of myoepithelial layer in each papillary tumor was confirmed by immunostains with specific myoepithelial markers, p63 and CD10.
  • The excisional biopsy specimen exhibited displaced fragments of benign epithelial cells within granulation tissue at the needle manipulation site, indicating that iatrogenic epithelial cell displacement did occur in this case.
  • It remains undetermined whether the nodal papilloma was derived from the papilloma of the mastectomy or if it arose de novo from the breast tissue inclusion of the sentinel node.
  • [MeSH-major] Breast Neoplasms / pathology. Lymph Nodes / pathology. Papilloma, Intraductal / secondary. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Axilla. Biomarkers, Tumor / analysis. DNA, Neoplasm / analysis. Female. Humans. Lymphatic Metastasis. Mastectomy. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379415.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


33. Ceçener G, Egeli U, Tunca B, Taşdelen I, Tolunay S, Bilgel N: Importance of novel sequence alterations in the FHIT gene on formation of breast cancer. Tumori; 2007 Nov-Dec;93(6):597-603
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of novel sequence alterations in the FHIT gene on formation of breast cancer.
  • AIMS AND BACKGROUND: The character, role and impact of FHIT gene alterations, for which recent studies have shown that the gene has a role in the early stage of carcinogenesis in breast cancer, are still unclear.
  • Thus, the current study evaluated FHIT gene mutations from breast tissue of women with malignant and benign breast disease and to elucidate the frequency and type of mutations in this gene.
  • PATIENTS AND METHODS: Mutations in exons 5-9 of the FHIT gene were screened using the intronic primer pairs in 83 breast (67 malignant and 16 benign) tissue samples by single-strand conformational polymorphism and sequencing analysis.
  • RESULTS: FHIT mutations were detected in 13 of the 67 malignant cases (19.4%) and 2 of the 16 benign cases (12.5%).
  • CONCLUSIONS: Our data contribute significantly to that currently known about the presence of FHIT gene mutations on the formation of breast cancer.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Breast Neoplasms / genetics. Breast Neoplasms / pathology. Mutation. Neoplasm Proteins / genetics
  • [MeSH-minor] Adult. Aged. Alanine. Carcinoma / genetics. Female. Fibroadenoma / genetics. Frameshift Mutation. Glutamine. Humans. Hyperplasia / genetics. Lymphatic Metastasis. Middle Aged. Phenylalanine. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Sequence Analysis, DNA. Threonine

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. (L)-ALANINE .
  • Hazardous Substances Data Bank. Glutamine .
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • Hazardous Substances Data Bank. L-Threonine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18338496.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; 0RH81L854J / Glutamine; 2ZD004190S / Threonine; 47E5O17Y3R / Phenylalanine; EC 3.6.- / Acid Anhydride Hydrolases; OF5P57N2ZX / Alanine
  •  go-up   go-down


34. Tse GM, Tan PH, Moriya T: The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast. J Clin Pathol; 2009 May;62(5):407-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast.
  • Papillary lesions of the breast represent a heterogeneous group with differing biological behaviour.
  • Correct diagnosis is crucial but may be difficult, as many benign and malignant papillary lesions have similar appearances.
  • A panel of CK5/6, p63 and neuroendocrine markers can be useful in the diagnostic investigation of problematic papillary lesions of the breast.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Papillary / diagnosis. Papilloma / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Diagnosis, Differential. Female. Humans. Keratins / analysis. Neoplasm Proteins / analysis. Nerve Tissue Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126567.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 68238-35-7 / Keratins
  • [Number-of-references] 33
  •  go-up   go-down


35. Shin JH, Han BK, Choe YH, Nam SJ, Park W, Im YH: Ultrasonographic detection of occult cancer in patients after surgical therapy for breast cancer. J Ultrasound Med; 2005 May;24(5):643-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasonographic detection of occult cancer in patients after surgical therapy for breast cancer.
  • OBJECTIVE: The purpose of this study was to investigate the efficacy of ultrasonography in detecting an occult malignancy after surgery for breast cancer and to assess the imaging and clinical findings associated with a recurrence.
  • METHODS: During a 4-year period, 3329 bilateral whole-breast ultrasonographic examinations were performed to detect occult malignancies clinically and mammographically in 1968 asymptomatic patients after breast cancer surgery.
  • The questionable lesions were lymph nodes in 42 and masses in 15; of these lesions, 24 were malignant (true-positive) and 33 were benign (false-positive).
  • The locations of the recurrent lesions were the regional lymph nodes in 14 cases (4, axillary fossa; 4, interpectoral; 4, internal mammary; and 2, supraclavicular lymph nodes) and the breast and mastectomy bed in 7 cases.
  • The mean size of the malignant lymph nodes was larger than that of the benign lymph nodes.
  • CONCLUSIONS: Postoperative follow-up ultrasonography showed occult malignancies clinically and mammographically in 1.2% of the patients who had been treated for breast cancer.
  • Familiarity with the common location of a tumor recurrence is essential for making an accurate ultrasonographic evaluation in these patients.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / ultrasonography. Mastectomy. Neoplasm Recurrence, Local / ultrasonography. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Combined Modality Therapy. Diagnostic Errors. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15840796.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Shukla R, Pooja B, Radhika S, Nijhawan R, Rajwanshi A: Fine-needle aspiration cytology of extramammary neoplasms metastatic to the breast. Diagn Cytopathol; 2005 Apr;32(4):193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration cytology of extramammary neoplasms metastatic to the breast.
  • Fine-needle aspiration (FNA) biopsy is the first-line investigation in any breast lump and hence cytomorphological recognition of nonmammary metastatic tumors to the breast and their distinction from primary tumors is important.
  • Metastatic breast neoplasms diagnosed over a 6-yr period from 1997 to 2002 were retrieved from the database of the Department of Cytopathology and the clinical, cytopathological, histochemical, and immunohistochemical findings were correlated with the histopathology of the primary tumor.
  • Fifteen cases of metastatic breast neoplasms were encountered constituting 1.47% of all malignant tumors of the breast diagnosed on FNA.
  • There were 14 female patients and one male patient aged 13-80 yr.
  • The preaspiration clinical diagnosis was either a benign breast lump or a malignancy (primary vs. metastatic).
  • The breast lump was the initial presentation in four cases and the cytodiagnosis of a metastatic malignancy lead to the subsequent detection of the primary malignancy.
  • The presence of unusual cytomorphological patterns on breast FNA should alert the cytopathologist to the possibility of a metastatic breast neoplasm, even if not suspected clinically.
  • A detailed history of the patient, clinical correlation, and immunocytochemistry helps in establishing an accurate diagnosis, which avoids unnecessary surgery and ensures appropriate treatment.
  • [MeSH-major] Breast / pathology. Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / secondary
  • [MeSH-minor] Adolescent. Adult. Biopsy, Fine-Needle. Child. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / pathology. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15754368.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Owens CL, Basaria S, Nicol TL: Metastatic breast carcinoma involving the thyroid gland diagnosed by fine-needle aspiration: a case report. Diagn Cytopathol; 2005 Aug;33(2):110-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic breast carcinoma involving the thyroid gland diagnosed by fine-needle aspiration: a case report.
  • We discuss a case of a 64-yr-old female with a history of breast carcinoma, who presented with pain and swelling in her neck 5 yrs after being diagnosed with breast cancer.
  • A fine-needle aspiration (FNA) of the larger thyroid nodule showed malignant epithelial cells with features consistent with breast carcinoma in a background of benign thyroid epithelial cells and colloid.
  • The case was signed out as metastatic breast carcinoma.
  • Subsequent FNA and biopsy of her right shoulder lesion also revealed metastatic breast carcinoma with similar morphology to the material in the thyroid FNA.
  • [MeSH-major] Carcinoma, Ductal, Breast. Thyroid Gland / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Breast Neoplasms / complications. Breast Neoplasms / pathology. Breast Neoplasms / therapy. Female. Humans. Middle Aged. Neoplasm Metastasis / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16007653.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Somiari SB, Somiari RI, Heckman CM, Olsen CH, Jordan RM, Russell SJ, Shriver CD: Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer; 2006 Sep 15;119(6):1403-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories.
  • Matrix metalloproteinase (MMP) 2 and 9 are involved in cancer invasion and metastasis, and increased levels occur in serum and plasma of breast cancer (BC) patients.
  • In our study, we measured concentration and activity of MMP2/9 in sera of 345 donors classified as low risk (Gail score <1.7), high risk (HR) (Gail score > or =1.7), benign disease or BC.
  • Kruskal-Wallis and Mann-Whitney nonparametric tests showed that total-MMP2 concentration is higher in HR compared to control (p = 0.012), benign (p = 0.001) and cancer (p = 0.007).
  • Active MMP2 (aMMP2) concentration is higher in control than benign and cancer (p < 0.001, respectively).
  • Total and aMMP9 concentrations are higher in cancer than benign (p < 0.001, p = 0.002, respectively).
  • Total-MMP2 and total-MMP9 activities are lower in control than benign (p < 0.001, p = 0.002, respectively) and cancer (p < 0.001, respectively).
  • Total-MMP2 and MMP9 activities are also higher in cancer than benign (p = 0.004, p < 0.001) and HR (p = 0.008, p = 0.007, respectively).
  • Our study provides evidence supporting the potential role of serum MMP2/9 as biomarkers for breast disease classification.
  • [MeSH-major] Breast Diseases / enzymology. Breast Neoplasms / enzymology. Matrix Metalloproteinase 2 / blood. Matrix Metalloproteinase 9 / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Breast / enzymology. Carcinoma, Intraductal, Noninfiltrating / enzymology. Female. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Cancer. 2007 Jul 1;121(1):216-8; author reply 219-23 [17315186.001]
  • (PMID = 16615109.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


39. Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ: Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer; 2005 May 1;103(9):1778-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: During a review of 1877 breast biopsy specimens in a nested case-control study of benign breast disease and breast carcinoma risk, the authors identified 13 biopsy specimens with DCIS that were originally diagnosed as benign.
  • Because each of these women was initially given a benign diagnosis, they received no treatment beyond the diagnostic biopsy.
  • RESULTS: When compared with women with nonproliferative lesions, the odds ratio (OR) for the development of invasive breast carcinoma among those with retrospectively identified DCIS (n = 6) was 13.5 (95% confidence interval [CI], 3.7-49.7).
  • The OR for the development of any subsequent invasive or in situ breast carcinoma event (n = 10) was 20.1 (95% CI, 6.1-66. 5).
  • All 10 breast carcinoma events (100%) were in the ipsilateral breast.
  • CONCLUSIONS: These results provided further evidence that patients with DCIS who received no treatment beyond a diagnostic biopsy were at substantially increased risk for developing ipsilateral invasive breast carcinoma, and that the increased risk in this setting was seen in DCIS of low, intermediate, and high nuclear grades.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma in Situ / diagnosis. Carcinoma, Ductal, Breast / diagnosis
  • [MeSH-minor] Adult. Biopsy. Case-Control Studies. Cell Nucleus / pathology. Cohort Studies. Female. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasms / diagnosis. Neoplasms / therapy. Retrospective Studies. Risk Factors. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15770688.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA046475; United States / NCI NIH HHS / CA / CA050385; United States / NCI NIH HHS / CA / CA087969
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


40. Harmer V: Breast cancer. Part 3: advanced cancer and psychological implications. Br J Nurs; 2008 Sep 25-Oct 8;17(17):1088, 1090, 1092 passim
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer. Part 3: advanced cancer and psychological implications.
  • This is the last article in this 3-part series on breast cancer.
  • The previous two articles have outlined the principles behind breast awareness and breast health, detailing common benign breast diseases, types of breast cancer and staging, and treatment for breast cancer, including surgery, chemotherapy, radiotherapy and endocrine treatment.
  • The series concludes by giving information on advanced disease, including when a patient presents late with a fungating breast lesion, or if the disease has metastasized from the breast to other organs.
  • Lymphoedema is also described and discussed, and the latter half of this article discusses psychological implications of breast cancer, from diagnosis through the individual treatments.
  • [MeSH-major] Breast Neoplasms / nursing
  • [MeSH-minor] Adaptation, Psychological. Female. Humans. Lymphedema / etiology. Lymphedema / nursing. Neoplasm Metastasis. Palliative Care. Skin Ulcer / etiology. Skin Ulcer / nursing. Social Support

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19186363.001).
  • [ISSN] 0966-0461
  • [Journal-full-title] British journal of nursing (Mark Allen Publishing)
  • [ISO-abbreviation] Br J Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 30
  •  go-up   go-down


41. Craig S, Bui-Mansfield LT, Lusk JD: Radiology pathology conference of Brooke Army Medical Center: trichoblastoma of breast. Clin Imaging; 2009 Jul-Aug;33(4):311-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiology pathology conference of Brooke Army Medical Center: trichoblastoma of breast.
  • The differential diagnosis of a superficial breast lesion detected on mammography typically includes seborrheic keratosis, dermal nevus, epidermal inclusion cyst, and basal cell carcinoma with subcutaneous invasion [Kopans DB.
  • Breast Imaging. 3rd ed.
  • The case presented is of a trichoblastoma of the superficial breast.
  • Trichoblastoma is a benign skin neoplasm that is rarely found in the breast.
  • This case describes and correlates the findings of trichoblastoma of the breast on mammography, sonography, and histology.
  • [MeSH-major] Breast Neoplasms / diagnosis. Mammography / methods
  • [MeSH-minor] Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19559355.001).
  • [ISSN] 1873-4499
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Goufman EI, Moshkovskii SA, Tikhonova OV, Lokhov PG, Zgoda VG, Serebryakova MV, Toropygin IY, Vlasova MA, Safarova MR, Makarov OV, Archakov AI: Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions. Biochemistry (Mosc); 2006 Apr;71(4):354-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions.
  • The thermostable fraction of serum samples from patients with ovarian, uterus, and breast cancers and benign ovarian tumor was analyzed using two-dimensional electrophoresis combined with MALDI-TOF(-TOF)-mass spectrometry.
  • Of them, alpha-1-acid glycoprotein and clusterin are expressly down-regulated in breast cancer, whereas transthyretin is decreased specifically in ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Electrophoresis, Gel, Two-Dimensional / methods. Neoplasm Proteins / blood. Proteome / analysis. Proteomics / methods
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / blood. Breast Neoplasms / metabolism. Female. Humans. Middle Aged. Ovarian Neoplasms / blood. Ovarian Neoplasms / metabolism. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Uterine Neoplasms / blood. Uterine Neoplasms / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16615854.001).
  • [ISSN] 0006-2979
  • [Journal-full-title] Biochemistry. Biokhimii︠a︡
  • [ISO-abbreviation] Biochemistry Mosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Proteome
  •  go-up   go-down


43. Fu Q, Yao GY, Tang XL, Chen LR, Zheng ZX: [Microsatellite instability and allele-specific chromosome 3p deletion in breast cancer and precancerous lesions]. Zhonghua Zhong Liu Za Zhi; 2007 Jan;29(1):34-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Microsatellite instability and allele-specific chromosome 3p deletion in breast cancer and precancerous lesions].
  • OBJECTIVE: To investigate the incidence and clinicopathologic significance of MSI and LOH on 3P in breast carcinoma and its precancerous lesions, intraductal papillary adenoma and ductal carcinoma in situ.
  • METHODS: 41 paired sporadic invasive breast carcinomas, 13 archival precancerous lesion specimens of the breast and 14 couples of benign hyperplasia were collected.
  • There was no MSI in benign hyperplasia.
  • Of the 11 loci examined, D3S1295, D3S1029 and D3S1038 were identified as the locus with most frequent LOH which were all correlated significantly with some clinicopathological parameters such as histological type, lymph node metastasis in breast cancer, while D3S1295 and D3S1029 were the most frequent markers in precancerous lesions.
  • Positive expression of hMLH1 and hMSH2 protein was detected in breast carcinomas in scattered distribution and their positive rate was 45% and 40% , respectively.
  • CONCLUSION: Defective expression of MMR genes is closely associated with the development of breast cancer.
  • MSI indicates poor histological differentiation in breast carcinoma.
  • D3S1766 and D2S2739 might be the sensitive sites to detect MSI in breast carcinoma and precancerous lesions.
  • The smallest common LOH deletion regions seem likely to be situated between 3p14 and 3p25, indicating the existence of breast tumor related genes in those regions and some of them might affect tumor development.
  • [MeSH-major] Breast Neoplasms / pathology. Chromosome Deletion. Chromosomes, Human, Pair 3 / genetics. Microsatellite Instability. Precancerous Conditions / pathology
  • [MeSH-minor] Acid Anhydride Hydrolases / metabolism. Adaptor Proteins, Signal Transducing / metabolism. Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Breast / metabolism. Breast / pathology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. DNA Mismatch Repair. Female. Humans. Hyperplasia. Immunohistochemistry. Loss of Heterozygosity. Lymphatic Metastasis. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Staging. Nuclear Proteins / metabolism. Polymerase Chain Reaction. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575691.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / MLH2 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


44. Hagemann T, Binder C, Binder L, Pukrop T, Trümper L, Grimshaw MJ: Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol; 2005 Nov;24(11):766-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells.
  • There is increased staining of endothelins (ET-1, -2, and -3) and receptors (ET-RA and -RB) in invasive breast tumors compared to nonneoplastic tissue, and ETs stimulate MCF-7 cell invasion in vitro.
  • We analyzed ETstimulation of benign and transformed mammary epithelial cells, and whether expression of ETs is sufficient to induce invasiveness.
  • In breast cancer patient serum, ET-1 was increased in those patients with lymph node metastases compared to those with no lymph node involvement; ETs, however, had no mitogenic effect on breast tumor cell lines in vitro.
  • The benign mammary epithelial cell line, hTERT-HME1, and the poorly invasive breast tumor cell line MCF-7 secreted low levels of ET-1, while the invasive cell lines SKBR3 and MDAMB231 secreted high levels.
  • In contrast to transformed cells, ET stimulation or overexpression did not induce an invasive phenotype in benign cells.
  • Benign cells do not respond to ETs, and ET expression is not sufficient to induce invasion; however, the level of ET production by tumor cells correlates with their invasiveness, and increasing expression of the ET axis promotes breast tumor cell invasion via both receptors, while MMP-14 is induced via ET-RA.
  • [MeSH-major] Breast Neoplasms / metabolism. Endothelins / biosynthesis. Epithelial Cells / metabolism. Receptor, Endothelin A / biosynthesis. Receptor, Endothelin B / biosynthesis
  • [MeSH-minor] Calcium / metabolism. Cell Line. Cell Line, Tumor. Endothelin-1 / blood. Endothelin-1 / metabolism. Enzyme Induction. Female. Humans. Lymphatic Metastasis. Mammary Glands, Human / metabolism. Mammary Glands, Human / pathology. Matrix Metalloproteinases / biosynthesis. Neoplasm Invasiveness. Phenotype. Signal Transduction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274297.001).
  • [ISSN] 1044-5498
  • [Journal-full-title] DNA and cell biology
  • [ISO-abbreviation] DNA Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endothelin-1; 0 / Endothelins; 0 / Receptor, Endothelin A; 0 / Receptor, Endothelin B; EC 3.4.24.- / Matrix Metalloproteinases; SY7Q814VUP / Calcium
  •  go-up   go-down


45. Sanders ME, Page DL, Simpson JF, Schuyler PA, Dale Plummer W, Dupont WD: Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies. Cancer; 2006 Apr 1;106(7):1453-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies.
  • BACKGROUND: Radial scars (RS) are benign breast lesions that have been implicated as independent risk factors for invasive breast carcinoma (IBC).
  • METHODS: A retrospective cohort study of 9556 women who underwent biopsy between 1950-1986 and enrolled in the Nashville Breast Cohort was performed to investigate the association between RS in a benign breast biopsy and the risk of IBC.
  • Although the presence of RS in a benign breast biopsy mildly elevates the risk of IBC risk, the current analysis indicated that this risk can be largely attributed to the category of coexistent PD.
  • [MeSH-major] Breast / pathology. Breast Diseases / complications. Breast Neoplasms / etiology. Carcinoma / etiology
  • [MeSH-minor] Adult. Aged. Biopsy. Case-Control Studies. Female. Humans. Hyperplasia / complications. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16502407.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30-CA68485; United States / NCI NIH HHS / CA / P50-CA098131; United States / NCI NIH HHS / CA / R01-CA50468
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Nissan A, Jager D, Roystacher M, Prus D, Peretz T, Eisenberg I, Freund HR, Scanlan M, Ritter G, Old LJ, Mitrani-Rosenbaum S: Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients. Br J Cancer; 2006 Mar 13;94(5):681-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients.
  • The presence of metastases in lymph nodes is the most powerful prognostic factor in breast cancer patients.
  • Routine histological examination of lymph nodes has limited sensitivity for the detection of breast cancer metastases.
  • The aim of the present study was to develop a multimarker reverse transcriptase-polymerase chain reaction (RT-PCR) assay for the detection of minimal residual disease in sentinel nodes of breast cancer patients.
  • RNA was extracted from 30 sentinel lymph nodes (SLN) obtained from 28 patients, three primary breast cancers (positive controls), three lymph nodes from patients with benign diseases, and peripheral blood lymphocytes of 10 healthy volunteers (negative controls).
  • Among the 30 SLN analysed, breast cancer metastases were detected in six SLNs by routine histology, in eight by IHC and in 15 by RT-PCR.
  • This method may prove to be of value in breast cancer staging and prognosis evaluation.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Breast Neoplasms / genetics. Breast Neoplasms / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Case-Control Studies. DNA Primers. Female. Humans. Immunohistochemistry. Lymph Nodes / pathology. Lymphatic Metastasis. Neoplasm Staging / methods. Neoplasm, Residual. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Feb 24;342(8):525-33 [10684910.001]
  • [Cites] Lancet. 1999 Sep 11;354(9182):896-900 [10489948.001]
  • [Cites] Breast Cancer Res Treat. 1999 Nov;58(2):137-40 [10674878.001]
  • [Cites] Oncol Rep. 2000 May-Jun;7(3):561-6 [10767368.001]
  • [Cites] Ann Surg. 2000 Jun;231(6):795-803 [10816622.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1468-75 [11230493.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2055-61 [11280766.001]
  • [Cites] Breast Cancer Res Treat. 2001 Apr;66(3):249-54 [11510696.001]
  • [Cites] Clin Breast Cancer. 2003 Apr;4 Suppl 1:S49-54 [12756079.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] Ann Oncol. 2003 Aug;14(8):1241-5 [12881386.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1750-6 [14583780.001]
  • [Cites] Am J Clin Pathol. 2004 May;121(5):637-43 [15151203.001]
  • [Cites] Am Surg. 2004 May;70(5):414-9 [15156949.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):828-37; discussion 837-40 [15166962.001]
  • [Cites] Semin Oncol. 2004 Jun;31(3):304-10 [15190486.001]
  • [Cites] Semin Oncol. 2004 Jun;31(3):426-36 [15190501.001]
  • [Cites] Cancer. 1980 Jun 15;45(12):2917-24 [7388735.001]
  • [Cites] Lancet. 1990 Jun 30;335(8705):1565-8 [1972494.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2986-90 [8187086.001]
  • [Cites] Virchows Arch. 1995;425(6):617-29 [7535166.001]
  • [Cites] Am J Pathol. 1996 Feb;148(2):649-56 [8579127.001]
  • [Cites] Bone Marrow Transplant. 1996 Sep;18 Suppl 1:S18-20 [8899163.001]
  • [Cites] JAMA. 1998 Oct 28;280(16):1410-5 [9801000.001]
  • [Cites] Genomics. 1998 Nov 15;54(1):70-8 [9806831.001]
  • [CommentIn] Br J Cancer. 2006 Jun 5;94(11):1761; author reply 1762 [16670723.001]
  • (PMID = 16495929.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA Primers
  • [Other-IDs] NLM/ PMC2361196
  •  go-up   go-down


47. Siegmann KC, Baur A, Vogel U, Kraemer B, Hahn M, Claussen CD: Risk-benefit analysis of preoperative breast MRI in patients with primary breast cancer. Clin Radiol; 2009 Apr;64(4):403-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk-benefit analysis of preoperative breast MRI in patients with primary breast cancer.
  • AIM: To analyse and compare the risks and benefits of preoperative breast MRI (BMRI) in patients with primary breast cancer (PBC), and to determine the influence of mammographic breast density (BD) and histological tumour type (TT).
  • MATERIALS AND METHODS: One hundred and nineteen patients who underwent preoperative bilateral breast MRI for staging of PBC during a 1-year period from July 2005 to August 2006 were prospectively evaluated.
  • Biopsies of benign MRI detected lesions were defined as disadvantageous.
  • Seventeen women underwent mastectomy instead of breast conservation, eight patients underwent extended excision, 21 additional lesions were clarified by MRI intervention, and two ultrasound-detected lesions were not biopsied because of negative MRI.
  • Twelve patients (10.1%) had additional biopsies of MRI-detected benign lesions, and therefore, had an unfavourable outcome due to BMRI.
  • The percentage of additional biopsies of benign lesions (10.1%) seems acceptable.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Neoplasms, Ductal, Lobular, and Medullary / pathology. Preoperative Care / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / ultrasonography. Carcinoma, Lobular / pathology. Carcinoma, Lobular / ultrasonography. Carcinoma, Medullary / pathology. Carcinoma, Medullary / ultrasonography. Female. Humans. Magnetic Resonance Imaging / methods. Mammography. Middle Aged. Needs Assessment. Neoplasm Staging. Prospective Studies. Risk Assessment. Treatment Outcome. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19264186.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


48. Tan PH, Jayabaskar T, Yip G, Tan Y, Hilmy M, Selvarajan S, Bay BH: p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. Mod Pathol; 2005 Dec;18(12):1527-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study.
  • Breast phyllodes tumors are fibroepithelial neoplasms whose clinical behavior is difficult to predict on histology.
  • Representative areas from 250 (75%) benign, 54 (16%) borderline and 31 (9%) malignant phyllodes tumors were selected for construction of tissue microarrays using the 2 mm punch.
  • Stromal p53 and CD117 protein expression was associated with tumor grade (P < 0.05).
  • Although positive p53 stromal immunohistochemical detection may corroborate histologic malignancy, it is CD117 protein expression in phyllodes tumor stromal cells that may be of potential utility in predicting recurrent disease.
  • [MeSH-major] Breast Neoplasms / diagnosis. Phyllodes Tumor / diagnosis. Proto-Oncogene Proteins c-kit / metabolism. Tissue Array Analysis / methods. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258510.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


49. Neagu A, Muscă S, Slătineanu S, Pricop M: [Breast conservative surgery]. Rev Med Chir Soc Med Nat Iasi; 2005 Jan-Mar;109(1):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast conservative surgery].
  • Breast conservative therapy is considered an adequate therapeutical method for early stage breast cancer.
  • Breast conservative treatment consists of partial mastectomy, axillary dissection and radiotherapy.
  • The frozen sections examination provides prompt differentiation between benign/malign lesions and precise assessment of the oncologic margins of the specimen.
  • Preoperative marking of nonpalpable breast lesion with hook wire represents a progress for breast conservative treatment.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy, Segmental / methods
  • [MeSH-minor] Female. Humans. Neoplasm Staging. Radiotherapy, Adjuvant. Sentinel Lymph Node Biopsy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607830.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 18
  •  go-up   go-down


50. Kärjä V, Alafuzoff I: Protein p62 common in invaginations in benign meningiomas--a possible predictor of malignancy. Clin Neuropathol; 2006 Jan-Feb;25(1):37-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein p62 common in invaginations in benign meningiomas--a possible predictor of malignancy.
  • Expression of p62 has been seen in inclusions in neoplasias like hepatocellular and breast carcinomas but also in neuronal inclusions of degenerative brain disorders.
  • MATERIAL: The study material included 45 benign meningiomas of postmenopausal women operated in Kuopio University Hospital between 1994 and 2002.
  • CONCLUSION: Our results indicate that in the benign not recurrent meningiomas, signs of functioning proteosomal system, can be detected using the p62 labeling.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Biomarkers, Tumor / analysis. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Aged. Brain / metabolism. Brain / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Postmenopause

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465773.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / SQSTM1 protein, human
  •  go-up   go-down


51. Wang ZC, Buraimoh A, Iglehart JD, Richardson AL: Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays. Breast Cancer Res Treat; 2006 Jun;97(3):301-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays.
  • Phyllodes tumors of the breast are biphasic stromal and epithelial tumors histologically similar to benign fibroadenomas, but with a neoplastic stromal component.
  • In a single case of phyllodes tumor containing a malignant epithelial component the malignant epithelium and stroma partially share an LOH genotype, suggesting a common precursor cell for the biphasic malignant components.
  • [MeSH-major] Breast Neoplasms / genetics. Fibroadenoma / genetics. Loss of Heterozygosity. Neoplasms, Multiple Primary / genetics. Neoplasms, Second Primary / genetics. Oligonucleotide Array Sequence Analysis. Phyllodes Tumor / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Cell Transformation, Neoplastic / genetics. DNA, Neoplasm / genetics. Epithelial Cells / pathology. Female. Gene Expression Profiling. Genome, Human. Humans. Stromal Cells / pathology

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791486.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / NCI P50 CA89393-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


52. Xing Y, Zhao JH, Wang TS, Qiao WL, Che WJ: [The role of 18F-FDG SPECT-CT in detecting recurrence and metastases in breast cancer patients with elevated tumor markers]. Zhonghua Zhong Liu Za Zhi; 2009 Feb;31(2):129-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of 18F-FDG SPECT-CT in detecting recurrence and metastases in breast cancer patients with elevated tumor markers].
  • OBJECTIVE: To compare retrospectively the role of (18)F-FDG SPECT-CT and conventional imaging in the detection of recurrence and metastases in postoperative breast cancer patients with elevated level of tumor markers, and to evaluate the impact of (18)F-FDG SPECT-CT on the management of breast cancer patients.
  • METHODS: (18)F-FDG SPECT-CT was performed in 35 breast cancer patients with suspected recurrence based on elevated level of serum tumor markers.
  • The final diagnosis of recurrent breast cancer was confirmed by either pathology or observation by imaging during the follow-up for more than 1 year.
  • RESULTS: Among the 35 patients, the final diagnosis of recurrence or metastasis was established in 19 patients.
  • Of the 114 sites of increased FDG uptake, 93 were interpreted as malignant and 21 as benign.
  • CONCLUSION: In postoperative breast cancer patients with elevated level of tumor markers during the follow-up, (18)F-FDG SPECT-CT is more sensitive for detecting recurrence and metastases than conventional imaging.
  • [MeSH-major] Breast Neoplasms / pathology. Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Breast Neoplasms, Male / blood. Breast Neoplasms, Male / pathology. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Radiopharmaceuticals. Retrospective Studies. Whole Body Imaging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538891.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


53. França SR, Caldas D, Alcebíades V 2nd, de Oliveira CA: [Mucoepidermoid carcinoma of the thyroid: a case report and literature review]. Arq Bras Endocrinol Metabol; 2006 Oct;50(5):968-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Carcinoma mucoepidermóide de tireóide: relato de caso e revisão da literatura.
  • The mucoepidermoid carcinoma is a neoplasia that usually occurs at salivary glands, breast, pancreas and gastrointestinal tract.
  • Although the majority of cases of mucoepidermoid carcinoma of the thyroid (MECT) show a benign evolution, this paper describes a patient with an aggressive tumor.
  • [MeSH-minor] Calcitonin / analysis. Female. Humans. Middle Aged. Mucins / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis. Thyroid Gland / pathology. Thyroidectomy. Whole Body Imaging

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160225.001).
  • [ISSN] 0004-2730
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Mucins; 9007-12-9 / Calcitonin
  • [Number-of-references] 26
  •  go-up   go-down


54. Fuchsjaeger MH, Flöry D, Reiner CS, Rudas M, Riedl CC, Helbich TH: The negative predictive value of electrical impedance scanning in BI-RADS category IV breast lesions. Invest Radiol; 2005 Jul;40(7):478-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The negative predictive value of electrical impedance scanning in BI-RADS category IV breast lesions.
  • OBJECTIVES: We sought to prospectively assess the value of electrical impedance scanning (EIS) in discriminating benign from malignant lesions classified as BI-RADS category IV in mammography in comparison with ultrasound (US), with a special focus on negative prediction.
  • RESULTS: Histology proved 37 lesions malignant, 91 benign.
  • CONCLUSIONS: With a NPV of 97.1% of EIS in BI-RADS category IV breast lesions, a negative result in these lesions could be firm indication to manage them as BI-RADS-category III and refer patients for a 6-month short-interval follow-up rather than performing a biopsy.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Electric Impedance. Ultrasonography, Mammary
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15973141.001).
  • [ISSN] 0020-9996
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Oldenburg A, Albrecht T: [Baseline and contrast-enhanced ultrasound of the liver in tumor patients]. Ultraschall Med; 2008 Oct;29(5):488-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Baseline and contrast-enhanced ultrasound of the liver in tumor patients].
  • Conventional sonography is the most commonly used modality for liver imaging in tumor patients.
  • The majority of liver metastases are hypoechoic and well defined in baseline ultrasound (US), while detection of isoechoic or small liver metastases <1 cm is difficult and the differentiation of liver metastases from benign liver lesions and other malignant liver tumors can be impossible with baseline US.
  • Furthermore, the typical enhancement patterns of the different benign and malignant liver lesions allow reliable characterization and differentiation from liver metastases in the majority of cases.
  • This paper provides information about the advantages and expedient application of contrast-enhanced ultrasound (CEUS) in tumor patients.
  • [MeSH-major] Contrast Media. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography. Neoplasm Metastasis / ultrasonography
  • [MeSH-minor] Adult. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Colonic Neoplasms / pathology. Colonic Neoplasms / ultrasonography. Diagnosis, Differential. Female. Humans. Middle Aged. Neovascularization, Pathologic / ultrasonography. Reproducibility of Results. Sarcoma, Ewing / pathology. Sarcoma, Ewing / ultrasonography. Ultrasonography, Doppler / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ultraschall Med. 2009 Apr;30(2):125-7 [19340726.001]
  • (PMID = 19241505.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


56. Viehweg P, Bernerth T, Heinig A, Kiechle M, Buchmann J, Koelbl H, Laniado M, Helen Heywang-Köbrunner S: MR-guided intervention in women at high hereditary risk of breast cancer due to both family and personal history of breast cancer. Breast J; 2006 Nov-Dec;12(6):549-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR-guided intervention in women at high hereditary risk of breast cancer due to both family and personal history of breast cancer.
  • The purpose of this study was to assess the value of magnetic resonance imaging (MRI)-guided intervention in women with a significant hereditary susceptibility to breast cancer due to both family and personal history of breast cancer (heterozygote risk >20%).
  • MR examinations (1.0 T, T1-weighted 3D FLASH, 0.15 mmol Gd-DTPA/kg body weight, prone position) were performed using a system which allows vacuum-assisted breast biopsy or wire localization.
  • Twenty-three benign histologic results were verified by an MR-guided intervention, retrospective correlation of imaging and histology and by subsequent follow-up.
  • Absent enhancement was confirmed by short-term re-imaging of the non-compressed breast and by follow-up.
  • [MeSH-major] Biopsy, Needle. Breast Neoplasms / diagnosis. Genetic Predisposition to Disease. Magnetic Resonance Imaging, Interventional
  • [MeSH-minor] Adult. Aged. Female. Heterozygote. Humans. Middle Aged. Neoplasm Recurrence, Local. Predictive Value of Tests


57. Yen JY, Ko CH, Yen CF, Yang MJ, Wu CY, Juan CH, Hou MF: Quality of life, depression, and stress in breast cancer women outpatients receiving active therapy in Taiwan. Psychiatry Clin Neurosci; 2006 Apr;60(2):147-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life, depression, and stress in breast cancer women outpatients receiving active therapy in Taiwan.
  • The aims of the present study were to compare the quality of life (QoL), depression and stress between patients with malignant breast cancer and those with benign breast tumors.
  • The present study also examined the factors related to QoL among the patients who were receiving active treatment for breast cancer.
  • Among the 97 patients participating in the study, 73 patients were diagnosed as having malignant breast cancer (malignant group) and 24 as having benign tumors (benign group).
  • Quality of life, depression and stress were compared between the malignant and benign groups, and the factors related to QoL were also examined.
  • Depression was significantly associated with QoL for both the malignant and benign groups, and the stress from health problem was the most significant predictors for QoL among the malignant group.
  • The breast cancer patients suffered more severe psychological difficulty under active treatment than did the benign group patients.
  • [MeSH-major] Breast Neoplasms / psychology. Breast Neoplasms / therapy. Depression / etiology. Quality of Life / psychology. Stress, Psychological / etiology
  • [MeSH-minor] Adult. Demography. Family / psychology. Female. Health Status. Humans. Middle Aged. Neoplasm Staging. Psychology. Severity of Illness Index. Surveys and Questionnaires


58. Nam EJ, Yun MJ, Oh YT, Kim JW, Kim JH, Kim S, Jung YW, Kim SW, Kim YT: Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol; 2010 Mar;116(3):389-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI.
  • RESULTS: Histopathology showed benign tumors in 25 patients, borderline tumors in 13 patients, and malignant tumors in 95 patients.
  • In distinguishing malignant/borderline from benign ovarian tumors, the accuracy of PET/CT (0.921) was higher than that of pelvis US (0.830) and abdomino-pelvic CT or pelvis MRI (0.749; P=0.013).
  • In addition, PET/CT detected new, unexpected co-existing malignant tumors in five (3.8%) cases including two thyroid tumors, two breast tumors, and one pancreatic neuroendocrine cancer.
  • CONCLUSION: PET/CT is superior to pelvis US, abdomino-pelvic CT, and pelvic MRI for diagnosis of malignant ovarian tumors and is useful in revealing metastatic ovarian cancer and co-existing malignant tumors.
  • [MeSH-major] Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. ROC Curve. Radiopharmaceuticals. Tomography, X-Ray Computed. Ultrasonography, Doppler. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19926121.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


59. Engohan-Aloghe C, Hottat N, Cosaert J, Boutemy R, Fayt I, Noël JC: Evaluation of accuracy of fine needle aspiration cytology in BI-RADS3 category breast lesions: cytohistological correlation in 337 cases. Cytopathology; 2010 Jun;21(3):161-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of accuracy of fine needle aspiration cytology in BI-RADS3 category breast lesions: cytohistological correlation in 337 cases.
  • OBJECTIVE: To evaluate the accuracy of fine needle aspiration cytology (FNAC) in BI-RADS3 breast lesions.
  • RESULTS: The histological diagnosis showed that 88% (59/67) of BI-RADS3 breast lesions were benign.
  • However, the correlation between cytology and histology showed that most of these lesions were benign and that finally FNAC remains a useful and accurate test in the management of these lesions.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Breast / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Neoplasm Staging. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744191.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


60. Ławicki S, Czygier M, Bedkowska E, Wojtukiewicz M, Szmitkowski M: Comparative evaluation of plasma levels and diagnostic values of macrophage-colony stimulating factor in patients with breast cancer and benign tumors. Pol Arch Med Wewn; 2008 Sep;118(9):464-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative evaluation of plasma levels and diagnostic values of macrophage-colony stimulating factor in patients with breast cancer and benign tumors.
  • The direct production of this cytokine has been reported in tumor cell lines in vitro and in solid tumors in vivo.
  • OBJECTIVES: In the present study, the levels of M-CSF in patients with breast cancer and in those with a benign breast tumor were evaluated.
  • PATIENTS AND METHODS: The study group was made up of 70 patients with breast cancer and 20 patients with benign tumors and the control group of 30 healthy women.
  • RESULTS: Statistically higher levels of M-CSF and CA 15-3 were found in breast cancer patients as compared to the benign tumor and control groups.
  • CONCLUSIONS: The above data suggests that M-CSF might be useful in both diagnostics and differential diagnosis of benign tumors and breast cancer (except for the lowest degree of the clinical progression).
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Macrophage Colony-Stimulating Factor / blood
  • [MeSH-minor] Adult. Aged. CA-125 Antigen / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. Poland. Predictive Value of Tests. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18846980.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


61. Schulz-Wendtland R, Bock K, Aichinger U, de Waal J, Bader W, Albert US, Duda VF: [Ultrasound examination of the breast with 7.5 MHz and 13 MHz-transducers: scope for improving diagnostic accuracy in complementary breast diagnostics?]. Ultraschall Med; 2005 Jun;26(3):209-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ultrasound examination of the breast with 7.5 MHz and 13 MHz-transducers: scope for improving diagnostic accuracy in complementary breast diagnostics?].
  • [Transliterated title] Mamma-Sonographie mit 7.5 MHz versus 13 MHz: Ist eine Verbesserung der diagnostischen Sicherheit im Rahmen der komplementären Mammadiagnostik möglich?
  • AIM: Complementary diagnostic methods in early diagnosis of breast cancer are used to increase diagnostic accuracy and minimize unnecessary invasive diagnostic procedures.
  • Aim of the following prospective, open multicenter clinical study was to define the value of high-frequency breast ultrasound with 13 MHZ transducers compared to standard breast ultrasound with 7.5 MHz.
  • METHOD: Data of 810 female patients, aged 45 to 60 years, with 819 suspicious breast lesions evaluated by four participating centres between October 1996 and December 1997.
  • Standardised breast ultrasound was performed uniformly using a AU4 IDEA diagnostic ultrasound system by Esaote-Biomedica in addition to a standardised procedure of clinical examination and standard-2view-mammography.
  • RESULTS: The histopathological evaluation showed 435 benign and 384 malignant findings.
  • High-frequency breast ultrasound (13 MHz) proved to have a higher diagnostic accuracy compared to standard breast ultrasound (7,5 MHz) regardless of tumour size.
  • CONCLUSIONS: We conclude that high-frequency ultrasound is a valueable additive tool especially in the diagnosis of small tumours, improving diagnostic safety and reducing unnecessary invasive diagnostic procedures.
  • [MeSH-major] Breast Diseases / ultrasonography. Breast Neoplasms / ultrasonography. Ultrasonography, Mammary / methods
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Staging. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948057.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


62. Erbas B, Provenzano E, Armes J, Gertig D: The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat; 2006 May;97(2):135-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The natural history of ductal carcinoma in situ of the breast: a review.
  • METHODS: We identified relevant publications of studies on: follow-up studies of DCIS initially misdiagnosed as benign, studies of recurrence of DCIS as invasive cancer, autopsy studies, studies of risk factors for DCIS, animal studies and studies that used mathematical models to study growth of DCIS and invasive cancer.
  • RESULTS: The most direct evidence regarding the progression of DCIS to invasive cancer comes from studies where DCIS was initially misdiagnosed as benign and treated by biopsy alone.
  • [MeSH-major] Breast Neoplasms / etiology. Carcinoma, Intraductal, Noninfiltrating / etiology
  • [MeSH-minor] Disease Progression. Female. Humans. Neoplasm Invasiveness / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16319971.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 93
  •  go-up   go-down


63. Ma X, Chen C, Xiong H, Li Y: Transforming growth factorβ1 L10P variant plays an active role on the breast cancer susceptibility in Caucasian: evidence from 10,392 cases and 11,697 controls. Breast Cancer Res Treat; 2010 Nov;124(2):453-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factorβ1 L10P variant plays an active role on the breast cancer susceptibility in Caucasian: evidence from 10,392 cases and 11,697 controls.
  • In view of the essential role of transforming growth factorβ1 (TGFB1) on both inhibiting the development of early benign breast tumors as well as promoting tumor invasion, the association of TGFB1 L10P polymorphism and breast cancer risk has been widely reported, but results of previous studies were somewhat contradictory and underpowered.
  • To overcome the limitations of individual study and to understand the real situation, we conducted a systematic review and meta-analysis towards the association between TGFB1 L10P polymorphism and breast cancer.
  • Conclusively, this meta-analysis strongly suggests that TGFB1 L10P polymorphism may play a low penetrance role in breast cancer susceptibility in Caucasian.
  • [MeSH-major] Breast Neoplasms / genetics. European Continental Ancestry Group / genetics. Polymorphism, Genetic. Transforming Growth Factor beta1 / genetics
  • [MeSH-minor] Case-Control Studies. Female. Gene Frequency. Genetic Predisposition to Disease. Humans. Neoplasm Invasiveness. Odds Ratio. Phenotype. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349130.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


64. Ko E, Han W, Lee JW, Cho J, Kim EK, Jung SY, Kang MJ, Moon WK, Park IA, Kim SW, Kim KS, Lee ES, Min KH, Kim SW, Noh DY: Scoring system for predicting malignancy in patients diagnosed with atypical ductal hyperplasia at ultrasound-guided core needle biopsy. Breast Cancer Res Treat; 2008 Nov;112(1):189-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of this study was to determine factors that predict under-evaluation of malignancy in patients diagnosed with atypical ductal hyperplasia (ADH) at ultrasound-guided core needle biopsy (CNB), and to develop a prediction algorithm for scoring the possibility of a diagnosis upgrade to malignancy based on clinical, radiological and pathological factors.
  • This system was able to identify a subset of patients with lesions likely to be benign, indicating that imaging follow-up rather than surgical excision may be appropriate.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Diagnostic Imaging. Hyperplasia / pathology. Hyperplasia / ultrasonography
  • [MeSH-minor] Biopsy, Needle. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Carcinoma, Ductal, Breast / ultrasonography. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Intraductal, Noninfiltrating / ultrasonography. Female. Humans. Mammography. Middle Aged. Neoplasm Staging. Prognosis. ROC Curve. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18060577.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


65. Jukic DM, Drogowski LM, Davie JR: Carcinoma ex spiradenoma/cylindroma confirmed by immunohistochemical and molecular loss-of-heterozygosity profiling. Am J Dermatopathol; 2009 Oct;31(7):702-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma ex spiradenoma/cylindroma confirmed by immunohistochemical and molecular loss-of-heterozygosity profiling.
  • Histopathological exam revealed a benign eccrine spiradenoma/cylindroma and an intermixed carcinoma, with a differential diagnosis of either primary eccrine carcinoma or mammary carcinoma metastatic to the spiradenoma/cylindroma.
  • The mammary carcinomas showed disparate LOH at 5 of 7 (right breast) and 4 of 7 (left breast) informative genetic loci, establishing these carcinomas as separate primary neoplasms.
  • This neoplasm is referred to in the literature as carcinoma ex spiradenoma/cylindroma and spiradenocylindrocarcinoma.
  • [MeSH-minor] Aged. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Loss of Heterozygosity. Neoplasms, Second Primary / pathology. Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19684510.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Papachristopoulou G, Avgeris M, Scorilas A: Expression analysis and study of KLK4 in benign and malignant breast tumours. Thromb Haemost; 2009 Feb;101(2):381-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis and study of KLK4 in benign and malignant breast tumours.
  • The purpose of this study was the expression analysis and study of KLK4 in benign and malignant breast tumours.
  • Total RNA was isolated from 16 benign and 45 malignant breast tissue specimens.
  • Relative quantification analysis was performed using the comparative C(T) method 2(-DeltaDeltaC)(T) KLK4 expression was found to vary in both patients' cohorts; however, a statistically significant elevation of the KLK4 mRNA levels was observed in malignant compared to benign tumour patients.
  • ROC and logistic regression analysis recommended that KLK4 gene expression may be used as a new potential biomarker in breast cancer.
  • [MeSH-major] Biomarkers, Tumor / genetics. Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Kallikreins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Cell Line, Tumor. Female. Humans. Logistic Models. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Prognosis. RNA, Messenger / analysis. ROC Curve. Receptors, Progesterone / analysis. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190825.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Progesterone; EC 3.4.21.- / Kallikreins; EC 3.4.21.- / kallikrein 4
  •  go-up   go-down


67. Drukier AK, Ossetrova N, Schors E, Krasik G, Grigoriev I, Koenig C, Sulkowski M, Holcman J, Brown LR, Tomaszewski JE, Schnall MD, Sainsbury R, Lokshin AE, Godovac-Zimmermann J: High-sensitivity blood-based detection of breast cancer by multi photon detection diagnostic proteomics. J Proteome Res; 2006 Aug;5(8):1906-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-sensitivity blood-based detection of breast cancer by multi photon detection diagnostic proteomics.
  • Sensitivity and specificity of about 95% have been achieved for blood-based detection of breast cancer in pilot studies on 250 patients and 95 controls.
  • Pilot studies indicate that this methodology may also allow differentiation of malignant breast cancer from benign lesions and can provide similar sensitivity and specificity for other epithelial cancers such as prostate cancer, ovarian cancer and melanoma.
  • [MeSH-major] Biomarkers, Tumor / blood. Blood. Breast Neoplasms. Neoplasm Proteins / analysis. Photons. Proteomics / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunoassay / methods. Interleukin-6 / blood. Interleukin-8 / blood. Middle Aged. Prostate-Specific Antigen / blood. Sensitivity and Specificity. Statistics as Topic. Tumor Necrosis Factor-alpha / blood. Vascular Endothelial Growth Factor A / blood

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Blood.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889412.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-6; 0 / Interleukin-8; 0 / Neoplasm Proteins; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Endothelial Growth Factor A; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


68. Schor AP, Carvalho FM, Kemp C, Silva ID, Russo J: S100P calcium-binding protein expression is associated with high-risk proliferative lesions of the breast. Oncol Rep; 2006 Jan;15(1):3-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S100P calcium-binding protein expression is associated with high-risk proliferative lesions of the breast.
  • Benign breast diseases represent the vast majority of diagnosis in breast pathology.
  • However, the limited capability in identifying lesions at high risk of breast cancer evolution is an increasing problem in clinical practice.
  • In the present study, we tested the hypothesis that the overexpression of S100P calcium-binding protein, previously identified in the very early stages of breast carcinogenesis, could be used as a marker to differentiate lesions at high risk of malignant evolution.
  • In addition to S100P, the well-known proliferative marker, Ki-67, and estrogen receptor (ER) status were also assessed by immunohistochemistry in 155 samples from patients who submitted to stereotactic vacuum-assisted core biopsy due to breast microcalcifications.
  • The strong association between S100P and ER expression highlights the hypothesis about the possible role played by S100P in the very early stages of breast carcinogenesis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Diseases / pathology. Breast Neoplasms / diagnosis. Calcium-Binding Proteins / metabolism. Neoplasm Proteins / metabolism. Precancerous Conditions / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Middle Aged. Prognosis. Receptors, Estrogen / analysis. Risk

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16328027.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / S100P protein, human
  •  go-up   go-down


69. Gisterek I, Matkowski R, Lacko A, Sedlaczek P, Szewczyk K, Biecek P, Halon A, Staszek U, Szelachowska J, Pudelko M, Bebenek M, Harlozinska-Szmyrka A, Kornafel J: Serum vascular endothelial growth factors a, C and d in human breast tumors. Pathol Oncol Res; 2010 Sep;16(3):337-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum vascular endothelial growth factors a, C and d in human breast tumors.
  • Available evidence suggests that vascular endothelial growth factor (VEGF) a potent regulator of vasculogenesis and tumor angiogenesis may be a predictor of recurrence in breast cancer patients.
  • We sought to determine whether VEGF serum levels (VEGF-A, VEGF-C and VEGF-D) in 377 patients with malignant and benign breast tumors differ and whether there is association between vascular growth factors, clinicopathologic features and prognosis.
  • In Cox model values of angiogenic serum markers and recognized prognostic markers in breast cancer, VEGF-C turned out as independent prognostic factor.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Vascular Endothelial Growth Factor A / blood. Vascular Endothelial Growth Factor C / blood. Vascular Endothelial Growth Factor D / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Enzyme-Linked Immunosorbent Assay. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic / blood. Neovascularization, Pathologic / mortality. Neovascularization, Pathologic / pathology. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Jun 1;94(11):2855-61 [12115372.001]
  • [Cites] Oncogene. 2005 Jun 23;24(27):4370-9 [15806151.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):512-7 [16750560.001]
  • [Cites] World J Gastroenterol. 2007 Mar 28;13(12):1794-7; discussion 1797-8 [17465468.001]
  • [Cites] Indian J Med Res. 2007 Jun;125(6):747-51 [17704550.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4695-704 [16034044.001]
  • [Cites] Gynecol Oncol. 2005 Sep;98(3):467-83 [15982726.001]
  • [Cites] J Cell Mol Med. 2007 Jan-Feb;11(1):120-8 [17367506.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):270-8 [14716760.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2898-905 [10850435.001]
  • [Cites] Scand J Clin Lab Invest. 2002;62(5):343-50 [12387579.001]
  • [Cites] Tumour Biol. 2006;27(6):302-8 [17028465.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5407-14 [11454684.001]
  • [Cites] Ann Surg Oncol. 2004 Oct;11(10):928-33 [15383417.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1217-22 [12973845.001]
  • [Cites] Br J Cancer. 2007 Oct 8;97(7):978-85 [17912242.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):724-30 [15637689.001]
  • [Cites] Br J Cancer. 2005 Feb 14;92(3):553-61 [15668703.001]
  • [Cites] Angiogenesis. 2003;6(4):283-7 [15166496.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3121-8 [9738584.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jan;89(2):135-43 [15692755.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1999 Sep;24(5):426-30 [10542924.001]
  • [Cites] Breast Cancer Res Treat. 2001 Mar;66(2):159-64 [11437102.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3491-4 [11705867.001]
  • (PMID = 19821158.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D
  •  go-up   go-down


70. Chen Y, Zou TN, Wu ZP, Zhou YC, Gu YL, Liu X, Jin CG, Wang XC: Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer. Int J Biol Markers; 2010 Apr-Jun;25(2):59-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer.
  • AIMS: To investigate the diagnostic, predictive, and prognostic value of the detection of circulating tumor cells (CTCs) using a three-marker (CK19, hMAM and CEA) RT-PCR assay in patients with early breast cancer.
  • PATIENTS AND METHODS: Peripheral blood was obtained from 50 patients with early-stage breast cancer before any systemic adjuvant therapy and analyzed for the presence of CK-19, hMAM and CEA mRNA-positive CTCs using an RT-PCR assay.
  • The specificity of the primers used was evaluated in 20 healthy individuals, 24 patients with benign breast disease, and 30 patients with metastatic breast cancer.
  • RESULTS: The detection rate of three-marker-positive CTCs in the blood of patients with early breast cancer was 54.0%, significantly higher than in patients with benign breast disease and healthy blood donors (p=0.002 and p=0.000, respectively).
  • For early breast cancer, correlation analysis between detection of three-marker-positive CTCs and clinicopathological characteristics indicated that detection of threemarker-positive CTCs was significantly correlated with elevated serum CEA levels (p=0.001).
  • Detection of three-marker-positive CTCs was associated with relapse and might have important predictive and prognostic implications in early breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoembryonic Antigen / genetics. Carcinoma / diagnosis. Keratin-19 / genetics. Neoplasm Proteins / genetics. Neoplastic Cells, Circulating / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods. Uteroglobin / genetics
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / blood. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Line, Tumor. Disease Progression. Early Detection of Cancer / methods. Female. Humans. Mammaglobin A. Middle Aged. Prognosis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20586026.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


71. Granados-García M, Cortés-Flores AO, del Carmen González-Ramírez I, Cano-Valdez AM, Flores-Hernández L, Aguilar-Ponce JL: Follicular neoplasms of the thyroid: importance of clinical and cytological correlation. Cir Cir; 2010 Nov-Dec;78(6):473-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fine needle aspiration biopsy (FNAB) is useful for initial evaluation; nevertheless, malignancy is uncertain when follicular neoplasm is reported.
  • METHODS: We analyzed the clinical files of consecutive patients with cytological diagnoses of follicular neoplasm.
  • Definitive report showed 45 benign (60%) and 30 malignant (40%) cases.
  • Benign cases included 29 goiters, 11 follicular adenomas, and 5 cases of thyroiditis.
  • Malignant cases were comprised of 12 papillary carcinomas, 4 follicular carcinomas, 3 papillary carcinomas-follicular variant, 1 lymphoma, 1 teratoma, 5 medullary carcinomas, 2 insular carcinomas, 1 anaplastic carcinoma and 1 metastatic breast carcinoma.
  • Tumor size of benign lesions was 3.43 ± 2.04 cm, and 4.67 ± 2.78 (p = 0.049) for malignant lesions.
  • Age was 46.95 ± 15.39 years for benign lesions and 48.67 ± 17.28 for malignant lesions (p = 0.66).
  • [MeSH-major] Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Follicular. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Female. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21214982.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


72. Mussari S, Sabino Della Sala W, Busana L, Vanoni V, Eccher C, Zani B, Menegotti L, Tomio L: Full-dose intraoperative radiotherapy with electrons in breast cancer. First report on late toxicity and cosmetic results from a single-institution experience. Strahlenther Onkol; 2006 Oct;182(10):589-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Full-dose intraoperative radiotherapy with electrons in breast cancer. First report on late toxicity and cosmetic results from a single-institution experience.
  • PURPOSE: To investigate the feasibility of applying exclusive intraoperative radiation therapy (IORT) after conservative surgery in limited-stage breast carcinoma and to evaluate late effects and cosmetic results after this new conservative treatment.
  • PATIENTS AND METHODS: From October 2000 to November 2002, 47 consecutive patients with unifocal breast carcinoma up to a diameter of 2 cm received conservative surgery followed by IORT with electrons as the sole adjuvant local therapy.
  • During follow-up, a radiologic assessment with mammography and sonography was periodically performed and any breast-imaging alterations were reported.
  • RESULTS: After a follow-up ranging from 36 to 63 months (median, 48 months), 15 patients developed breast fibrosis (grade 2 in 14 patients, grade 3 in one patient), two patients presented with grade 3 skin changes, one patient developed a clinically relevant fat necrosis, and one patient showed breast edema and pain.
  • Two patients developed contralateral breast cancer and one distant metastases; no local relapses occurred.
  • In four patients (8%), mammographic and sonographic findings suggested malignant lesions and required a rebiopsy to confirm the benign nature of the lesion.
  • CONCLUSION: IORT in breast carcinoma is still an experimental treatment option for select patients with breast cancer and its application should be restricted to prospective trials.
  • Although preliminary data on local control are encouraging, a longer follow-up is needed to confirm the efficacy of IORT in breast cancer and to exclude that severe late complications compromise the cosmetic results or modify the radiologic breast appearance during follow-up increasing the need for additional investigations.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Electrons / therapeutic use. Neoplasm Recurrence, Local / prevention & control. Radiation Injuries / etiology. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods
  • [MeSH-minor] Aged. Feasibility Studies. Female. Humans. Intraoperative Care / methods. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17013572.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


73. Bektas N, Haaf At, Veeck J, Wild PJ, Lüscher-Firzlaff J, Hartmann A, Knüchel R, Dahl E: Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer; 2008;8:42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer.
  • METHODS: Using immunohistochemistry (IHC) we systematically analysed FOXM1 expression in human invasive breast carcinomas (n = 204) and normal breast tissues (n = 46) on a tissue microarray.
  • Additionally, using semiquantitative realtime PCR, a collection of paraffin embedded normal (n = 12) and cancerous (n = 25) breast tissue specimens as well as benign (n = 3) and malignant mammary cell lines (n = 8) were investigated for FOXM1 expression.
  • RESULTS: FOXM1 was found to be overexpressed in breast cancer in comparison to normal breast tissue both on the RNA and protein level (e.g.
  • CONCLUSION: FOXM1 may represent a novel breast tumour marker with prognostic significance that could be included into multi-marker panels for breast cancer.
  • Interestingly, we found a positive correlation between FOXM1 expression and HER2 status, pointing to a potential role of FOXM1 as a new drug target in HER2 resistant breast tumour, as FOXM1 inhibitors for cancer treatment were described recently.
  • [MeSH-major] Biomarkers, Tumor / genetics. Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Forkhead Transcription Factors / genetics. Gene Expression Regulation, Neoplastic. Genes, erbB-2
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Protein Array Analysis. RNA, Neoplasm. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Sampling Studies. Statistics, Nonparametric. Survival Analysis. Up-Regulation


74. Tonegutti M, Girardi V: Stereotactic vacuum-assisted breast biopsy in 268 nonpalpable lesions. Radiol Med; 2008 Feb;113(1):65-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic vacuum-assisted breast biopsy in 268 nonpalpable lesions.
  • PURPOSE: We evaluated the reliability of stereotactic vacuum-assisted breast biopsies (VAB) from our personal experience.
  • Inclusion criteria were nonpalpable lesions, undetectable by ultrasound and suspected at mammography (microcalcifications, circumscribed mass, architectural distortion), for which cytology and/or core biopsy could not provide a definite diagnosis.
  • On the basis of the Breast Imaging Reporting and Data System (BI-RADS) classification, 16 cases (7%) were graded as highly suspicious for malignancy (BI-RADS 5), 81 (34%) as suspicious for malignancy (BI-RADS 4b), 97 (40%) as indeterminate (BI-RADS 4a) and 46 (19%) as probably benign (BI-RADS 3).
  • RESULTS: In 28/268 lesions (10.5%) the biopsy could not be performed (nonidentification of the lesion; inaccessibility due to location or breast size).
  • Pathology revealed 100/240 (42%) malignant or borderline lesions and 140/240 (58%) benign lesions.
  • CONCLUSIONS: In our experience, VAB showed fair reliability in the diagnosis of nonpalpable breast lesions despite a portion of failed (10.5%), nonsignificant (5%) procedures and underestimated lesions (9%).
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Stereotaxic Techniques
  • [MeSH-minor] Adult. Aged. Calcinosis / diagnostic imaging. Calcinosis / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia. Mammary Glands, Human / pathology. Mammography. Middle Aged. Neoplasm Invasiveness. Reproducibility of Results. Vacuum

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2002 Aug;224(2):548-54 [12147855.001]
  • [Cites] Radiology. 1999 Jun;211(3):845-50 [10352614.001]
  • [Cites] AJR Am J Roentgenol. 1999 May;172(5):1405-7 [10227526.001]
  • [Cites] JAMA. 1999 May 5;281(17 ):1638-41 [10235159.001]
  • [Cites] Radiology. 1998 Jul;208(1):251-60 [9646821.001]
  • [Cites] Radiology. 1997 Mar;202(3):843-7 [9051043.001]
  • [Cites] Radiology. 1997 Apr;203(1):151-7 [9122384.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jul;171(1):35-40 [9648759.001]
  • [Cites] AJR Am J Roentgenol. 1999 Mar;172(3):683-7 [10063860.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):245-51 [14716757.001]
  • [Cites] Acta Radiol. 1997 Sep;38(5):815-20 [9332236.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):53-8 [10882245.001]
  • [Cites] Radiology. 1999 Mar;210(3):799-805 [10207484.001]
  • [Cites] Radiology. 2001 Feb;218(2):497-502 [11161168.001]
  • [Cites] Eur J Radiol. 2005 Aug;55(2):270-6 [16036159.001]
  • [Cites] Radiology. 1997 Aug;204(2):575-6 [9240556.001]
  • [Cites] Acta Radiol. 2003 Jul;44(4):387-91 [12846688.001]
  • [Cites] AJR Am J Roentgenol. 1992 Mar;158(3):521-6 [1310825.001]
  • [Cites] Radiographics. 1997 Sep-Oct;17(5):1233-52 [9308112.001]
  • [Cites] AJR Am J Roentgenol. 1996 Feb;166(2):341-6 [8553943.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jul;173(1):227-9 [10397131.001]
  • [Cites] Radiol Med. 2004 Oct;108(4):335-44 [15525887.001]
  • [Cites] Radiology. 2006 Apr;239(1):61-70 [16567483.001]
  • [Cites] Cancer. 2001 Jan 1;91(1):173-7 [11148574.001]
  • [Cites] Radiology. 1997 Nov;205(2):423-8 [9356623.001]
  • [Cites] Am Surg. 1997 Nov;63(11):988-95 [9358788.001]
  • [Cites] Clin Radiol. 2006 Mar;61(3):276-81 [16488210.001]
  • [Cites] Radiology. 1987 Oct;165(1):99-102 [3628796.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;101(3):291-7 [16823506.001]
  • [Cites] Radiology. 1994 Nov;193(2):359-64 [7972743.001]
  • [Cites] AJR Am J Roentgenol. 2000 Nov;175(5):1341-6 [11044038.001]
  • [Cites] Radiology. 2001 Mar;218(3):866-72 [11230668.001]
  • [Cites] Eur Radiol. 1998;8(3):377-85 [9510569.001]
  • [Cites] Eur Radiol. 2002 Mar;12(3):638-45 [11870480.001]
  • [Cites] Pathologica. 2002 Aug;94(4):182-9 [12325416.001]
  • [Cites] Radiology. 1984 Feb;150(2):335-7 [6691085.001]
  • (PMID = 18338128.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


75. McLaughlin RA, Scolaro L, Robbins P, Hamza S, Saunders C, Sampson DD: Imaging of human lymph nodes using optical coherence tomography: potential for staging cancer. Cancer Res; 2010 Apr 1;70(7):2579-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic assessment is the gold standard technique for the identification of metastatic involvement of lymph nodes in malignant disease, but can only be performed ex vivo and often results in the unnecessary excision of healthy lymph nodes, leading to complications such as lymphedema.
  • In this morphologic study, we show the capability of OCT to image nodal microarchitecture through an assessment of fresh, unstained ex vivo lymph node samples.
  • Examples include both benign human axillary lymph nodes and nodes containing metastatic breast carcinoma.
  • [MeSH-minor] Breast Neoplasms / pathology. Breast Neoplasms / ultrastructure. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / ultrastructure. Female. Humans. Lymphatic Metastasis. Neoplasm Staging / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20233873.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


76. Beyrouti MI, Beyrouti R, Khabir A, Ben Amar M, Frikha F, Dhieb N, Damak D, Abid M, Affes N, Boujelben S, Frikha M: [Fibrocystic mastopathy and cancer of the breast. About 111 cases]. Tunis Med; 2006 Oct;84(10):626-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fibrocystic mastopathy and cancer of the breast. About 111 cases].
  • [Transliterated title] Mastopathies fibrokystiques et cancers du sein. A propos de 111 cas.
  • METHODS: This work is a retrospective survey of 111 observations of isolated fibrocystic mastopathies or associated to a breast cancer among 542 women admitted for tumor of the breast during one period of 13 active years from 1991 to 2003.
  • The diagnosis has been gotten by anatomo-pathologic exam in 95.5% (106 cas) on the operative piece and 4.5% (5 cas) on a material of biopsy.
  • RESULTS: The fibrocystic mastopathy represented 30% of the set of the benign tumors of the breast.
  • They were associated to a breast cancer in 45 cases (40.5%).
  • The isolated benign fibrocystic mastopathy was observed in 66 cases with a middle age of 37 years, whereas the shapes associated to a breast carcinoma were noted in 45 cases.
  • CONCLUSION: The discovery of a mastopathy must search a luteal failure and risk factors of breast cancer notably a proliferative shape of mastopathy with atypies.
  • [MeSH-major] Breast Neoplasms. Carcinoma, Ductal, Breast. Fibrocystic Breast Disease
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Biopsy. Breast / pathology. Chi-Square Distribution. Data Interpretation, Statistical. Female. Humans. Menopause. Middle Aged. Neoplasm Staging. Parity. Predictive Value of Tests. Pregnancy. Retrospective Studies. Risk. Risk Factors. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17193854.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


77. Cao D, Polyak K, Halushka MK, Nassar H, Kouprina N, Iacobuzio-Donahue C, Wu X, Sukumar S, Hicks J, De Marzo A, Argani P: Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9. Breast Cancer Res; 2008;10(5):R91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Although lobular carcinoma in situ (LCIS) has traditionally been viewed as a marker of breast cancer risk, recent clinical, pathological and genetic analyses have supported the concept that LCIS is a low risk, direct precursor of invasive lobular carcinoma.
  • By comparing the gene expression profile of LCIS to that of benign breast epithelium and stroma, we identified several genes up and down regulated in LCIS.
  • RESULTS: We identified down regulation of claudin 4 and overexpression of matrix metalloproteinase 9 in LCIS relative to normal breast epithelium and stroma.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1999 Oct;189(2):161-8 [10547569.001]
  • [Cites] Histopathology. 2005 May;46(5):551-60 [15842637.001]
  • [Cites] Breast Cancer Res Treat. 2000 Aug;62(3):197-210 [11072784.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] JAMA. 1967 Jul 10;201(2):82-6 [6072345.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):741-51 [15696125.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9603-6 [16266975.001]
  • [Cites] Cancer. 2006 May 15;106(10):2104-12 [16604564.001]
  • [Cites] Adv Anat Pathol. 2006 Jul;13(4):157-65 [16858149.001]
  • [Cites] BMC Cancer. 2006;6:186 [16836752.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):427-37 [17325485.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):260-6 [17721269.001]
  • [Cites] Virchows Arch. 2007 Sep;451(3):669-80 [17609977.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):513-23 [18223478.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4606-13 [18559505.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14(1):5-7 [18598938.001]
  • [Cites] Hum Pathol. 2001 Mar;32(3):292-6 [11274638.001]
  • [Cites] Br J Cancer. 2001 Jun 1;84(11):1488-96 [11384099.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4320-4 [11389052.001]
  • [Cites] Int J Surg Pathol. 2001 Apr;9(2):127-31 [11484500.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] Lancet. 2003 Jan 11;361(9352):125-9 [12531579.001]
  • [Cites] Int J Cancer. 2003 Aug 20;106(2):208-15 [12800196.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):653-61 [12875984.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):970-5 [14601057.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):226-30 [14983936.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1627-33 [15111309.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2562-72 [15197797.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Cancer. 1974 Sep;34(3):554-63 [4853024.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1403-16 [8839545.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):297-301 [9149887.001]
  • [Cites] Br J Cancer. 1997;76(9):1131-3 [9365159.001]
  • [Cites] J Surg Oncol. 1998 Jan;67(1):41-6 [9457256.001]
  • [Cites] J Pathol. 1997 Dec;183(4):404-11 [9496256.001]
  • [Cites] Annu Rev Physiol. 1998;60:121-42 [9558457.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2876-80 [9661905.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4721-7 [9788628.001]
  • [Cites] Histopathology. 1999 Sep;35(3):195-200 [10469210.001]
  • [Cites] Semin Diagn Pathol. 1999 Aug;16(3):209-23 [10490198.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1531-6 [15619213.001]
  • [Cites] Oncol Rep. 2005 Feb;13(2):193-9 [15643498.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R296-305 [15743508.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]
  • (PMID = 18954444.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA088843; United States / NCI NIH HHS / CA / P50 CA88843
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLDN4 protein, human; 0 / Claudin-4; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2614499
  •  go-up   go-down


78. Czecior E, Namysłowski G, Misiołek M, Scierski W, Polok A, Lisowska G, Mrówka-Kata K, Orecka B, Pawlas P: [Strategy of the sinonasal tumors treatment]. Otolaryngol Pol; 2007;61(4):559-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They state about 1% of all tumors (kidney, testum, breast, pulmonary).
  • RESULTS: In the histological examination in 4 patients the benign neoplasm and in 22 patients malignant tumors were diagnosed.
  • On the basis of the CT and MRI examination as well as the description of the surgical procedure we stated that in 13 cases the primary localization of neoplasm was the maxillary sinus, in 5 cases ethmoidal cells, in 3 nasal cavity.
  • In one patient the estimation of primary tumor localization was not possible, because of the very large extension of the neoplasm.
  • The choice of the surgical procedure was depend on the tumor extension and localization.
  • [MeSH-major] Nose Neoplasms / diagnosis. Nose Neoplasms / surgery. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260251.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


79. Zhu Q, Hegde PU, Ricci A Jr, Kane M, Cronin EB, Ardeshirpour Y, Xu C, Aguirre A, Kurtzman SH, Deckers PJ, Tannenbaum SH: Early-stage invasive breast cancers: potential role of optical tomography with US localization in assisting diagnosis. Radiology; 2010 Aug;256(2):367-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage invasive breast cancers: potential role of optical tomography with US localization in assisting diagnosis.
  • PURPOSE: To investigate the potential role of optical tomography in the near-infrared (NIR) spectrum with ultrasonographic (US) localization as a means of differentiating early-stage cancers from benign lesions of the breast.
  • From this measurement, tumor angiogenesis was assessed on the basis of calculated total hemoglobin concentration (tHb) and was correlated with core biopsy results.
  • RESULTS: There were two in situ carcinomas (Tis), 35 T1 carcinomas, 24 T2-T4 carcinomas, and 114 benign lesions.
  • The mean maximum and mean average tHb of the benign group were 55.1 micromol/L +/- 22.7 and 39.1 micromol/L +/- 14.9, respectively.
  • Both mean maximum and mean average tHb levels were significantly higher in the malignant groups than they were in the benign group (P < .001).
  • CONCLUSION: The angiogenesis (tHb) contrast imaged by using the NIR technique with US holds promise as an adjunct to mammography and US for distinguishing early-stage invasive breast cancers from benign lesions.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2004 Jan;230(1):42-8 [14695385.001]
  • [Cites] J Pathol. 2004 Oct;204(2):140-6 [15376259.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6449-65 [2684393.001]
  • [Cites] Radiology. 1995 Jul;196(1):123-34 [7784555.001]
  • [Cites] Arch Surg. 1996 Mar;131(3):301-8 [8611096.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1053-5 [9870852.001]
  • [Cites] Radiology. 2004 Dec;233(3):857-67 [15567802.001]
  • [Cites] J Biomed Opt. 2004 Nov-Dec;9(6):1152-60 [15568935.001]
  • [Cites] Eur J Radiol. 2005 Apr;54(1):72-9 [15797295.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):263-70 [15799826.001]
  • [Cites] Appl Opt. 2005 Apr 10;44(11):2140-53 [15835360.001]
  • [Cites] Radiology. 2005 May;235(2):396-401 [15770039.001]
  • [Cites] Med Phys. 2005 Apr;32(4):1128-39 [15895597.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2429-49 [15901947.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2489-502 [15901950.001]
  • [Cites] Invest Radiol. 2005 Jun;40(6):328-35 [15905718.001]
  • [Cites] J Biomed Opt. 2005 Mar-Apr;10(2):024033 [15910106.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):229-37 [16034008.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):934-47 [16023382.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):925-33 [16023383.001]
  • [Cites] Radiology. 2005 Oct;237(1):57-66 [16183924.001]
  • [Cites] Breast Cancer Res. 2005;7(6):279-85 [16457705.001]
  • [Cites] Radiol Med. 2006 Apr;111(3):440-8 [16683089.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8828-33 [16731633.001]
  • [Cites] Technol Cancer Res Treat. 2006 Aug;5(4):365-80 [16866567.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):180-7 [17154175.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4014-9 [17360469.001]
  • [Cites] Radiology. 2007 May;243(2):350-9 [17400760.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5474-9 [17875777.001]
  • [Cites] Breast Cancer Res Treat. 2008 Mar;108(1):9-22 [17468951.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):539-44 [18267357.001]
  • [Cites] Acad Radiol. 2008 Jul;15(7):859-66 [18572121.001]
  • [Cites] Neoplasia. 2008 Oct;10(10):1028-40 [18813360.001]
  • [Cites] J Biomed Opt. 2008 Jul-Aug;13(4):044002 [19021330.001]
  • [Cites] Cancer. 2009 Apr 1;115(7):1363-80 [19197974.001]
  • [Cites] Radiology. 2009 Sep;252(3):665-72 [19567644.001]
  • [Cites] J Biomed Opt. 2009 Jul-Aug;14(4):044005 [19725717.001]
  • [Cites] Clin Radiol. 2000 Jan;55(1):40-4 [10650109.001]
  • [Cites] Radiology. 2000 Dec;217(3):841-8 [11110952.001]
  • [Cites] Ultrasound Med Biol. 2002 Jan;28(1):19-26 [11879948.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):347-54 [12082551.001]
  • [Cites] Opt Lett. 2003 Mar 1;28(5):337-9 [12659436.001]
  • [Cites] Neoplasia. 2003 Sep-Oct;5(5):379-88 [14670175.001]
  • (PMID = 20571122.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB002136
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2909434
  •  go-up   go-down


80. Terry G, Ho L, Londesborough P, Duggan C, Hanby A, Cuzick J: The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions. Br J Cancer; 2007 Jan 15;96(1):110-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions.
  • Immunohistochemical staining for FHIT and PCNA proteins was carried out in 451 breast lesions showing nonproliferative benign breast disease (BBD) (n=263), proliferative BBD without atypia (n=128), proliferative BBD with atypia (n=11), carcinoma in situ (n=15) or invasive carcinoma (n=34) and for EGFR protein in a subset of 71 of these cases.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. Breast Diseases / metabolism. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Neoplasm Proteins / biosynthesis. Proliferating Cell Nuclear Antigen / biosynthesis. Receptor, Epidermal Growth Factor / biosynthesis
  • [MeSH-minor] Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Oligonucleotide Array Sequence Analysis / methods. Polymerase Chain Reaction / methods. RNA / genetics. Sensitivity and Specificity. Staining and Labeling


81. Chin J, Konje JC, Hickey M: Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev; 2009;(4):CD007245
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
  • BACKGROUND: Adjuvant tamoxifen reduces the risk of breast cancer recurrence in women with estrogen receptor-positive breast cancer.
  • This systematic review considered the evidence that the LNG-IUS prevents the development of endometrial pathology in women taking tamoxifen as adjuvant endocrine therapy for breast cancer.
  • OBJECTIVES: To determine the effectiveness of the levonorgestrel intrauterine system in preventing the development of endometrial hyperplasia, polyps, and adenocarcinoma in pre and postmenopausal women taking adjuvant tamoxifen following breast cancer.
  • SEARCH STRATEGY: All reports which described randomised controlled trials of effects of the levonorgestrel intrauterine system on the endometrium in breast cancer patients taking adjuvant tamoxifen were obtained through searches of the Menstrual Disorders and Subfertility Group Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2009), MEDLINE (1996 to August 2009), EMBASE (1980 to August 2009), CINAHL (Cumulative Index to Nursing and Allied Health Literature) (1982 to August 2009).
  • SELECTION CRITERIA: Randomised controlled trials of women with breast cancer on adjuvant tamoxifen that compared endometrial surveillance or placebo alone versus the LNG-IUS.
  • Neither trial was sufficiently powered to detect whether LNG-IUS leads to significant changes in the incidence of endometrial hyperplasia or adenocarcinoma in tamoxifen users, nor whether LNG-IUS leads to any increased risk of breast cancer recurrence.
  • AUTHORS' CONCLUSIONS: The Mirena LNG-IUS appears to prevent the development of benign endometrial polyps in breast cancer patients taking tamoxifen, over a one-year period.
  • Larger studies are necessary to assess the effects of LNG-IUS in preventing endometrial hyperplasia and endometrial cancer, and to determine whether LNG-IUS might have an impact on the risk of breast cancer recurrence.
  • [MeSH-major] Breast Neoplasms / prevention & control. Contraceptive Agents, Female / administration & dosage. Endometrial Hyperplasia / prevention & control. Endometrial Neoplasms / prevention & control. Intrauterine Devices, Medicated. Levonorgestrel / administration & dosage
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / prevention & control. Antineoplastic Agents, Hormonal / adverse effects. Chemotherapy, Adjuvant. Female. Humans. Neoplasm Recurrence, Local / prevention & control. Polyps / chemically induced. Polyps / prevention & control. Randomized Controlled Trials as Topic. Tamoxifen / adverse effects


82. Puisieux A: [Inactivation of failsafe programs by Twist oncoproteins and tumor progression]. Ann Pharm Fr; 2008 Nov-Dec;66(5-6):278-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inactivation of failsafe programs by Twist oncoproteins and tumor progression].
  • [Transliterated title] Inactivation des systèmes de sauvegarde cellulaire par les oncoprotéines Twist et progression tumorale.
  • Hence, in benign tumors, aberrant mitogenic activity is counterbalanced by the induction of these oncosuppressive pathways, leading to either apoptosis or senescence which both limit tumor outgrowth.
  • Based on our work on Twist oncoproteins, we propose a presentation of recent data on cellular mechanisms by which cancer cells override the surveillance machinery and escape senescence and apoptosis, and we will describe the biological impact of this process on tumor metastasis.
  • [MeSH-major] Neoplasm Metastasis / pathology. Neoplasm Proteins / physiology. Nuclear Proteins / physiology. Repressor Proteins / physiology. Twist Transcription Factor / physiology
  • [MeSH-minor] Animals. Apoptosis / physiology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Aging / physiology. Disease Progression. Female. Gene Amplification / physiology. Genes, myc. Humans. Neoplasm Invasiveness. Neuroblastoma / metabolism. Neuroblastoma / pathology. Proto-Oncogene Proteins c-myc / physiology. Tumor Suppressor Protein p53 / physiology. Tumor Suppressor Proteins / antagonists & inhibitors. Tumor Suppressor Proteins / physiology. ras Proteins / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19061727.001).
  • [ISSN] 0003-4509
  • [Journal-full-title] Annales pharmaceutiques françaises
  • [ISO-abbreviation] Ann Pharm Fr
  • [Language] fre
  • [Publication-type] Addresses; English Abstract
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / Repressor Proteins; 0 / TWIST1 protein, human; 0 / TWIST2 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / Twist Transcription Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


83. Celis JE, Moreira JM, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans V, Rank F: Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. Mol Oncol; 2007 Jun;1(1):97-119
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.
  • The identification as well as the molecular characterization of breast precancerous lesions in terms of increased risk of progression and/or recurrence is becoming a critical issue today as improved non-surgical procedures are detecting cancer at an earlier stage.
  • The strategy we have been pursuing to identify early apocrine breast lesions is based on the postulate that invasive apocrine carcinomas evolve from epithelial cells in terminal duct lobular units (TDLUs) in a stepwise manner that involves apocrine metaplasia of normal breast epithelia, hyperplasia, atypia, and apocrine carcinoma in situ.
  • First, we identify specific protein biomarkers for benign apocrine metaplasia and thereafter we search for biomarkers that are highly overexpressed by pure invasive apocrine carcinomas.
  • Here we present studies in which we have used antibodies against components of a benign apocrine signature that includes 15-prostaglandin dehydrogenase (15-PGDH), a protein that is expressed by all benign apocrine lesions, and markers that are highly overexpressed by pure invasive apocrine carcinomas such as MRP14 (S100A9), psoriasin (S100A7), and p53 to identify precancerous lesions in sclerosing adenosis (SA) with apocrine metaplasia.
  • The latter is a benign proliferative lesion of the breast that exhibits an increase in the size of the TDLUs and characterized by retained two-cell lining, and myoepithelial (ME) and stromal hyperplasia.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Breast Neoplasms / metabolism. Fibrocystic Breast Disease / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis. Precancerous Conditions / metabolism
  • [MeSH-minor] Adult. Aged, 80 and over. Female. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Metaplasia / metabolism. Metaplasia / pathology. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):39-50 [11801722.001]
  • [Cites] Mod Pathol. 1994 Oct;7(8):813-8 [7838835.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):785-93; discussion 793 [12454517.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jul;104(1):75-85 [17009105.001]
  • [Cites] J Cell Biol. 1997 Dec 29;139(7):1873-84 [9412479.001]
  • [Cites] Adv Anat Pathol. 2004 Jan;11(1):1-9 [14676636.001]
  • [Cites] Eur J Radiol. 2005 Apr;54(1):6-14 [15797289.001]
  • [Cites] Am J Pathol. 1983 Feb;110(2):105-12 [6130702.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):146-9 [7819031.001]
  • [Cites] Radiographics. 1999 Oct;19 Spec No:S80-3 [10517446.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):459-72 [17157787.001]
  • [Cites] Am J Surg. 1990 May;159(5):473-8 [2334010.001]
  • [Cites] J Pathol. 2004 Mar;202(3):274-85 [14991892.001]
  • [Cites] Virchows Arch. 1998 Mar;432(3):255-60 [9532005.001]
  • [Cites] Am J Surg. 1993 Sep;166(3):237-43 [8368433.001]
  • [Cites] J Cutan Pathol. 1999 Mar;26(3):113-8 [10235375.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1316-23 [16835330.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):555-69 [15644556.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):26-41 [19383285.001]
  • [Cites] Anticancer Res. 1988 Nov-Dec;8(6):1217-22 [3064712.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):693-7 [10505026.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):13-8 [10658905.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):872-9 [11978511.001]
  • [Cites] Biochem Pharmacol. 2006 Nov 30;72(11):1622-31 [16846592.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Lab Invest. 2002 Jun;82(6):737-46 [12065684.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):323-9 [10880402.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):355-61 [10197443.001]
  • [Cites] Ir J Med Sci. 1989 Jun;158(6):137-40 [2570047.001]
  • [Cites] Recent Results Cancer Res. 1998;152:11-21 [9928543.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Trends Cell Biol. 1996 Sep;6(9):341-7 [15157431.001]
  • [Cites] J Cell Biol. 2007 Apr 9;177(1):87-101 [17420292.001]
  • [Cites] Breast Cancer Res. 2003;5(5):R151-6 [12927046.001]
  • [Cites] BMJ. 1997 Mar 29;314(7085):925-8 [9099114.001]
  • [Cites] J Dermatol Sci. 2007 Feb;45(2):147-50 [17071058.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]
  • [Cites] Virchows Arch. 2006 May;448(5):525-31 [16570182.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2805-9 [7872722.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):8-16 [12794751.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):261-72 [16807805.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1340-2 [11684218.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):470-9 [9469330.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7818-23 [16885386.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Med Princ Pract. 2007;16(1):1-14 [17159357.001]
  • [Cites] Subcell Biochem. 1998;31:205-62 [9932494.001]
  • [Cites] J Invest Dermatol. 1991 Oct;97(4):701-12 [1940442.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4782-90 [8840999.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):1033-67 [17158753.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2935-44 [16631754.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2529-37 [8640702.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1473-81 [16273201.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] FEBS J. 2005 Jan;272(1):2-15 [15634327.001]
  • [Cites] Ann N Y Acad Sci. 1990;586:49-52 [2141459.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2006 Oct;81(1-2):14-30 [16997128.001]
  • [Cites] Mol Cell Proteomics. 2006 Mar;5(3):462-83 [16316978.001]
  • [Cites] Adv Anat Pathol. 2002 May;9(3):185-97 [11981114.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):344-9 [16400324.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):349-54 [10197442.001]
  • [Cites] J Clin Pathol. 1995 Aug;48(8):737-42 [7560201.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):369-72 [7927943.001]
  • [Cites] Pathol Res Pract. 1997;193(11-12):753-8 [9521507.001]
  • [Cites] Eur J Gynaecol Oncol. 1992;13(4):309-15 [1325346.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):734-46 [15897740.001]
  • [Cites] Adv Anat Pathol. 2003 May;10(3):113-24 [12717115.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):207-14 [11141494.001]
  • [Cites] JAMA. 1995 Jan 11;273(2):149-54 [7799496.001]
  • [Cites] Breast Cancer Res. 2005;7(5):190-7 [16168137.001]
  • [Cites] Mol Cell Proteomics. 2003 Jun;2(6):369-77 [12832461.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1307-12 [17182657.001]
  • [Cites] Methods. 2003 Jul;30(3):247-55 [12798139.001]
  • [Cites] Am J Clin Pathol. 2000 May;113(5 Suppl 1):S3-18 [11993707.001]
  • [Cites] Nat Chem Biol. 2006 Dec;2(12):689-700 [17108987.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):675-81 [15220356.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):231-47 [16807803.001]
  • [Cites] Dev Biol. 1999 Feb 1;206(1):88-99 [9918697.001]
  • [Cites] Histopathology. 2001 Mar;38(3):221-4 [11260302.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):97-119 [19383289.001]
  • [Cites] Breast Cancer Res Treat. 2001 May;67(2):93-109 [11519870.001]
  • [Cites] Breast. 2002 Dec;11(6):466-72 [14965711.001]
  • [Cites] J Pathol. 2002 Mar;196(3):287-91 [11857491.001]
  • [Cites] J Mol Biol. 1993 Jun 20;231(4):982-98 [8515476.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6):642-6 [17145342.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Int J Cancer. 2000 Jun 15;86(6):835-41 [10842198.001]
  • [Cites] Med Mol Morphol. 2006 Mar;39(1):8-13 [16575508.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):638-42 [17136094.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1051-61 [15254552.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):749-51 [10797302.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):381-6 [3557440.001]
  • [Cites] J Biol Chem. 1975 May 25;250(10):4007-21 [236308.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):449-55 [12447674.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1076-91 [15252316.001]
  • [Cites] Differentiation. 1998 Aug;63(4):201-13 [9745711.001]
  • [Cites] Endocr Relat Cancer. 2001 Mar;8(1):47-61 [11350726.001]
  • [Cites] Mod Pathol. 1991 Jan;4(1):1-5 [2020652.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):387-94 [17079091.001]
  • [Cites] Histopathology. 2001 Oct;39(4):433-4 [11683946.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2328-38 [16314837.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11326-34 [16357139.001]
  • [Cites] Eur J Cancer. 2004 May;40(8):1179-87 [15110881.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jan;10(1):61-74 [15886887.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):492-522 [15695426.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):43-7 [11782356.001]
  • [Cites] Am J Surg Pathol. 1991 Jul;15(7):687-94 [2058763.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):327-44 [14754989.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):3003-9 [10383167.001]
  • [Cites] Pathology. 2006 Feb;38(1):16-20 [16484002.001]
  • [Cites] Hum Pathol. 1994 Apr;25(4):337-42 [8163266.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] J Endocrinol. 1992 Mar;132(3):R5-8 [1564416.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):84-96 [18516279.001]
  • [Cites] Cancer Detect Prev. 2001;25(3):262-7 [11425268.001]
  • (PMID = 19383289.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


84. De Cesare A, Fiori E, Burza A, Ciardi A, Bononi M, Izzo L, Volpino P, Cavallaro A, Cangemi V: Malignant fibrous histiocytoma of the breast. Report of two cases and review of the literature. Anticancer Res; 2005 Jan-Feb;25(1B):505-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the breast. Report of two cases and review of the literature.
  • Sarcomas of the breast are uncommon, accounting for less than 1% of all primary malignancies.
  • Two cases of this neoplasm are reported, with histological findings and surgical treatment.
  • The issue of radiation-induced lesions after surgery for carcinoma and the necessity for a correct preoperative diagnosis is examined.
  • A review of the available literature evaluates the histopathological and biological features of MFH of the breast, for which there are no prospective trials, owing to the rarity of this kind of neoplasm.
  • [MeSH-major] Breast Neoplasms / diagnosis. Histiocytoma, Benign Fibrous / diagnosis
  • [MeSH-minor] Adult. Aged. Breast / pathology. Female. Fibroblasts / metabolism. Humans. Immunohistochemistry. Lymphatic Metastasis. Mammography. Time Factors

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816619.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


85. Koensgen D, Oskay-Oezcelik G, Katsares I, Walle U, Klapp C, Mustea A, Stengel D, Porzsolt F, Lichtenegger W, Sehouli J, Nord-Ostdeutschen Gesellschaft für Gynäkologische Onkologie (NOGGO) working group "Quality of life": Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study. Support Care Cancer; 2010 Aug;18(8):931-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the phase II study, the capability of BSCL-O was evaluated by questionnaire-guided interviews of 200 patients with primary OC, recurrent OC, metastasized breast cancer, and benign ovarian tumors.
  • [MeSH-major] Breast Neoplasms / psychology. Ovarian Neoplasms / psychology. Quality of Life. Surveys and Questionnaires
  • [MeSH-minor] Adult. Aged. Female. Germany. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1994;30A(9):1326-36 [7999421.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):579-86 [16446330.001]
  • [Cites] Semin Oncol. 1999 Feb;26(1 Suppl 1):32-9 [10071971.001]
  • [Cites] West J Nurs Res. 1997 Jun;19(3):334-50 [9170991.001]
  • [Cites] Oncology (Williston Park). 1994 Dec;8(12):21-5; discussion 25, 29-30 [7888309.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1809-17 [11251013.001]
  • [Cites] Anticancer Res. 2009 Jul;29(7):2831-6 [19596970.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 Nov;19(11):1633-7 [6315445.001]
  • [Cites] J Obstet Gynaecol Can. 2004 Jul;26(7):627-31 [15248931.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):570-9 [8445433.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 2):S151-5 [7530679.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5605-12 [16110020.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(1):47-53 [11165129.001]
  • [Cites] Support Care Cancer. 2005 Apr;13(4):219-27 [15538640.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):907-15 [8039118.001]
  • [Cites] Gynecol Oncol. 1993 Aug;50(2):202-7 [8397153.001]
  • [Cites] Support Care Cancer. 1996 May;4(3):169-79 [8739648.001]
  • [Cites] Eur J Cancer. 2003 Jul;39(10):1402-8 [12826043.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13(6):741-8 [14675309.001]
  • [Cites] Eur J Cancer. 1990 Mar;26(3):345-52 [2141492.001]
  • (PMID = 19760286.001).
  • [ISSN] 1433-7339
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


86. Song J, Yang W, Shih IeM, Zhang Z, Bai J: Identification of BCOX1, a novel gene overexpressed in breast cancer. Biochim Biophys Acta; 2006 Jan;1760(1):62-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of BCOX1, a novel gene overexpressed in breast cancer.
  • The identification of tumor-associated antigens, which are specifically expressed in cancer tissues, is of utmost important for immunotherapy of breast cancer.
  • We have combined in silico screening and experimental expression analysis to identify genes that are differentially expressed in breast carcinomas compared with their corresponding normal tissues.
  • Using these approaches, we identified a novel gene, BCOX1, with overexpression in breast carcinoma.
  • RNA in situ hybridization shows that BCOX1 mRNA signal is mainly located in the cytoplasm of breast carcinoma epithelial cells, but not in those of normal epithelial cells, stroma cells and lymphocytes.
  • Furthermore, mRNA expression of BCOX1 was moderately elevated in ductal in situ carcinoma (DCIS), peaked in invasive breast carcinoma (IBC) and metastatic breast carcinoma cells (MET) whereas absent in benign ductal epithelial cells.
  • The predicted BCOX1 open reading frame of 666 bp encodes a putative protein of 222 amino acid residues with a calculated molecular weight of 2,4920 Da and a PI of 5.86.
  • This study warrants further investigations to explore the molecular functions of BCOX1, and to determine its potential diagnostic and therapeutic applications for breast cancer.
  • [MeSH-major] Antigens, Neoplasm / analysis. Breast Neoplasms / chemistry. Breast Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / genetics
  • [MeSH-minor] Chromosomes, Human, Pair 17. Computational Biology. Cytoplasm / chemistry. Epithelial Cells / chemistry. Female. Gene Expression Profiling. Humans. Molecular Sequence Data. Open Reading Frames. RNA, Messenger / analysis. Tissue Distribution


87. Gromov P, Gromova I, Bunkenborg J, Cabezon T, Moreira JM, Timmermans-Wielenga V, Roepstorff P, Rank F, Celis JE: Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. Mol Oncol; 2010 Feb;4(1):65-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast.
  • Breast cancer is by far the most common diagnosed form of cancer and the leading cause of cancer death in women today.
  • Clinically useful biomarkers for early detection of breast cancer could lead to a significant reduction in mortality.
  • Here we describe a detailed analysis using gel-based proteomics in combination with mass spectrometry and immunohistochemistry (IHC) of the tumour interstitial fluids (TIF) and normal interstitial fluids (NIF) collected from 69 prospective breast cancer patients.
  • To this end, we chose to use samples derived from a single tumour/benign tissue pair (patient 46, triple negative tumour), for which we had well-matched samples in terms of epithelial cell numbers, to generate the initial dataset.
  • In the second phase, we carried out a systematic computer assisted analysis of the 2D gels of the remaining 68 TIF samples in order to identify TIF 46 up-regulated proteins that were deregulated in 90% or more of all the available TIFs, thus representing common breast cancer markers.
  • This second phase singled out a set of 26 breast cancer markers, most of which were also identified by a complementary analysis using LC-MS/MS.
  • The expression of calreticulin, cellular retinoic acid-binding protein II, chloride intracellular channel protein 1, EF-1-beta, galectin 1, peroxiredoxin-2, platelet-derived endothelial cell growth factor, protein disulfide isomerase and ubiquitin carboxyl-terminal hydrolase 5 were further validated using a tissue microarray containing 70 malignant breast carcinomas of various grades of atypia.
  • The next steps, which include biomarker prioritization based on the hierarchal evaluation of these markers, antibody and antigen development, assay development, analytical validation, and preliminary testing in the blood of healthy and breast cancer patients, are discussed.
  • [MeSH-major] Biomarkers / metabolism. Biomarkers, Tumor / metabolism. Breast Neoplasms / diagnosis. Neoplasm Staging / classification
  • [MeSH-minor] Body Fluids / chemistry. Calreticulin / metabolism. Chloride Channels / metabolism. Early Diagnosis. Electrophoresis, Gel, Two-Dimensional / methods. Female. Galectin 1 / metabolism. Humans. Immunohistochemistry. Peptide Elongation Factor 1 / metabolism. Peroxiredoxins / metabolism. Prognosis. Protein Disulfide-Isomerases / metabolism. Proteomics / statistics & numerical data. Thymidine Phosphorylase / metabolism. Up-Regulation


88. Kuijper A, de Vos RA, Lagendijk JH, van der Wall E, van Diest PJ: Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors. Am J Clin Pathol; 2005 May;123(5):690-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors.
  • We studied cell cycle-regulating proteins in phyllodes tumor pathogenesis by immunohistochemical analysis for Ki-67, cyclin A, cyclin D1, retinoblastoma protein (pRb), p53, p16INK4A, bcl-2, and p21waf1 in the epithelium and stroma of 40 primary (benign, 21; borderline, 8; malignant, 11) and 7 recurrent tumors of different grades.
  • Stromal overexpression of p16INK4A, p53, cyclin A, pRb, and p21waf1 correlated significantly with tumor grade.
  • Stromal cyclin A expression was the best separating marker between tumor grades.
  • The stromal component of mammary phyllodes tumors displays an increasing level of cell cycle deregulation with higher tumor grade; the epithelial compartment mostly remains inconspicuous.
  • [MeSH-major] Breast Neoplasms / pathology. Cell Cycle. Cell Cycle Proteins / metabolism. Phyllodes Tumor / pathology. Stromal Cells / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis


89. Al-Khawari H, Kovacs A, Athyal R, Al-Manfouhi H, Fayaz MS, Madda JP: Breast magnetic resonance imaging: initial experience in Kuwait. Med Princ Pract; 2009;18(2):143-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast magnetic resonance imaging: initial experience in Kuwait.
  • OBJECTIVE: To report our initial experience of breast magnetic resonance imaging (MRI) in Kuwait in order to identify and characterize breast lesions.
  • SUBJECTS AND METHODS: In 58 patients ranging in age from 25 to 64 years, breast MRI was performed as a problem-solving tool (29); for suspicious local relapse of the treated breast (6); to search for a primary breast cancer in patients with metastatic axillary lymph nodes (5); for local staging of breast cancer (5); breast implants (6); screening in high-risk patients (3), and differentiation between inflammation and inflammatory carcinoma (4).
  • RESULTS: Seventy breast lesions (25 malignant, 38 benign and 7 lesions detected by MRI only) were identified in the 58 patients.
  • The sensitivity, specificity, and positive and negative predictive values of MRI in diagnosing malignant breast lesions were 96, 67, 71 and 95%, respectively, while the accuracy was 80%.
  • [MeSH-major] Breast. Breast Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Kuwait. Magnetic Resonance Imaging. Mass Screening / methods. Middle Aged. Neoplasm Staging / methods. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19204434.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


90. Elayat G, Selim AG, Wells CA: Cell cycle alterations and their relationship to proliferation in apocrine adenosis of the breast. Histopathology; 2009 Feb;54(3):348-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle alterations and their relationship to proliferation in apocrine adenosis of the breast.
  • AIMS: Apocrine adenosis (AA) is generally considered a benign disease of the breast.
  • The aim was to investigate the status of cell cycle proteins previously reported to be deregulated in breast cancer to identify their possible role in AA.
  • Furthermore, proliferation in AA (4.5%) was significantly higher than that of normal breast epithelium (1%).
  • [MeSH-major] Breast / pathology. Cell Cycle / physiology. Cell Proliferation. Fibrocystic Breast Disease / pathology
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / metabolism. Cell Cycle Proteins / metabolism. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236511.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins
  •  go-up   go-down


91. Bleiweiss IJ, Nagi CS, Jaffer S: Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. J Clin Oncol; 2006 May 1;24(13):2013-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma.
  • PURPOSE: Immunohistochemical (IHC) staining for cytokeratins (CK) is common practice in evaluating sentinel lymph nodes (SLNs) in patients with breast carcinoma.
  • Iatrogenic epithelial cell displacement and benign transport of breast epithelial cells into axillary lymph nodes are recently described phenomena.
  • We report 25 cases in which these factors probably resulted in benign epithelial cells in axillary SLNs (ie, false positivity).
  • METHODS: We reviewed 25 cases of CK-positive SLNs in which the epithelial cells had histologic and IHC characteristics different from their respective patients' underlying breast carcinomas.
  • RESULTS: In all cases, the cytologic features of the epithelial cells in the SLNs were benign, and 22 matched those of corresponding intraductal papillomas that were involved by or were separate from the DCIS in the original cores or surgical biopsies.
  • Nineteen cases showed benign epithelial cell displacement at the biopsy site.
  • Sentinel lymph nodes in breast carcinoma can be falsely positive.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Axilla. Cell Movement. Epithelial Cells / pathology. False Positive Reactions. Female. Humans. Immunohistochemistry. Keratins / analysis. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 May 1;24(13):1978-9 [16606969.001]
  • (PMID = 16606970.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


92. Dugina VB, Chipysheva TA, Ermilova VD, Gabbiani D, Chaponnier C, Vasil'ev IuM: [Distribution of actin isoforms in normal, dysplastic, and tumorous human breast cells]. Arkh Patol; 2008 Mar-Apr;70(2):28-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distribution of actin isoforms in normal, dysplastic, and tumorous human breast cells].
  • The distribution of beta- and gamma-cytoplasmic actins was compared in the normal cells and dysplastic malignant breast epithelial cells.
  • The authors' findings suggest that specific monoclonal antibodies to beta- and gamma-cytoplasmic actins may be used as supplementary markers that can differentiate benign and malignant breast neoplasms.
  • [MeSH-major] Actins / metabolism. Breast Neoplasms / metabolism. Fibroadenoma / metabolism. Fibrocystic Breast Disease / metabolism. Mammary Glands, Human / metabolism. Neoplasm Proteins / metabolism. Papilloma / metabolism
  • [MeSH-minor] Female. Humans. Protein Isoforms / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540438.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Actins; 0 / Neoplasm Proteins; 0 / Protein Isoforms
  •  go-up   go-down


93. Tse GM, Tan PH, Ma TK, Gilks CB, Poon CS, Law BK: CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast. J Clin Pathol; 2005 Nov;58(11):1185-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast.
  • BACKGROUND/AIMS: CD44s, the standard form of CD44, has been shown to be downregulated during malignant transformation of breast cancers.
  • It has also been reported recently to be a useful marker in differentiating between benign and malignant papillary lesions of the breast, with high expression in the former.
  • CD44s expression in benign and malignant papillary lesions was evaluated.
  • METHODS: CD44s expression was assessed by immunohistochemistry in 101 benign papillomas and 59 papillary carcinomas (seven invasive papillary carcinomas, 41 papillary ductal carcinomas in situ, and 11 ductal carcinomas involving papillomas).
  • Using CD44s positive staining to differentiate between benign and malignant papillary lesions gives a sensitivity, specificity, and accuracy of 45%, 92%, and 62%, respectively.
  • CONCLUSIONS: CD44s may be useful as an adjunct in the evaluation of morphologically problematic cases of papillary lesion of the breast.
  • [MeSH-major] Antigens, CD44 / metabolism. Biomarkers, Tumor / metabolism. Breast Neoplasms / diagnosis. Carcinoma, Papillary / diagnosis. Papilloma, Intraductal / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / metabolism. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Humans. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2004 Apr;19(2):465-71 [15024707.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3a):1665-70 [15274338.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5702-11 [15313910.001]
  • [Cites] J Mol Histol. 2004 Mar;35(3):211-31 [15339042.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):23-31 [15385106.001]
  • [Cites] Hum Pathol. 1988 Mar;19(3):276-89 [2450059.001]
  • [Cites] Am J Surg Pathol. 1990 Oct;14(10):939-47 [1698341.001]
  • [Cites] Cancer Cells. 1991 Sep;3(9):347-50 [1721518.001]
  • [Cites] J Cell Biol. 1992 Aug;118(4):971-7 [1380003.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(4):315-22 [1384226.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(4):323-30 [1384227.001]
  • [Cites] Curr Top Microbiol Immunol. 1993;184:47-63 [7508842.001]
  • [Cites] Bioessays. 1995 Jan;17(1):17-24 [7535522.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5424-33 [7585612.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(3):307-313 [8573713.001]
  • [Cites] J Clin Pathol. 1999 Nov;52(11):862-4 [10690183.001]
  • [Cites] Histopathology. 2000 Sep;37(3):232-40 [10971699.001]
  • [Cites] Arch Gynecol Obstet. 1996;258(3):125-35 [8781700.001]
  • [Cites] Clin Exp Metastasis. 1996 Oct;14(5):434-9 [8871537.001]
  • [Cites] Histopathology. 1998 Aug;33(2):107-16 [9762542.001]
  • [Cites] Virchows Arch. 1999 Jan;434(1):45-50 [10071234.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):625-32 [15832086.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jan;65(1):23-9 [11245336.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2539-46 [11745187.001]
  • [Cites] J Pathol. 2001 Nov;195(4):415-21 [11745672.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Mar;10(1):34-9 [11893033.001]
  • [Cites] Histopathology. 2003 Jun;42(6):546-54 [12786890.001]
  • [Cites] Virchows Arch. 2003 Jun;442(6):548-54 [12712335.001]
  • [Cites] Pol J Pathol. 2003;54(4):243-7 [14998292.001]
  • [Cites] Genomics. 1995 Nov 1;30(1):115-7 [8595891.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):513-8 [8621236.001]
  • [Cites] Eur J Surg Oncol. 1996 Jun;22(3):259-61 [8654608.001]
  • (PMID = 16254109.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD44S antigen
  • [Other-IDs] NLM/ PMC1770758
  •  go-up   go-down


94. Kallel R, Bahri Zouari I, Gouiaa N, Charfi S, Daoud E, Ayadi L, Makni S, Daoud J, Sellami Boudawara T: [Adenoid cystic carcinoma of the breast]. Cancer Radiother; 2009 Jul;13(4):323-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinoma of the breast].
  • [Transliterated title] Carcinome adénoïde kystique du sein.
  • Adenoid cystic carcinoma of the breast is a rare neoplasm, accounting for only 0.1% of all malignant breast tumours.
  • The clinical criteria is not specific and the radiographic examination showed a benign-appearing tumour.
  • The preoperative diagnosis is possible with fine-needle aspiration cytology.
  • The diagnosis is made by histological examination, presented a difficult differential diagnosis with cribriform carcinoma; so it is necessary to use histochemical or immunohistochemical techniques.
  • Compared to other locations, adenoid cystic carcinoma of the breast has a favorable prognosis.
  • The aim of our study is to describe the epidemiological, clinicopathological characteristics, the treatment and the prognosis of this rare type of breast tumour.
  • [MeSH-major] Breast Neoplasms. Carcinoma, Adenoid Cystic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Combined Modality Therapy / methods. Diagnosis, Differential. Female. Humans. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464219.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 30
  •  go-up   go-down


95. Ravindra S, Suguna BV: Cytomorphology of tubular adenoma breast--a case report. Indian J Pathol Microbiol; 2006 Apr;49(2):267-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphology of tubular adenoma breast--a case report.
  • Tubular adenoma a 'pure adenoma' is a benign neoplasm of breast presenting clinically like fibroadenoma.
  • We report cytological and histological features of tubular adenoma in a 24 year old female with brief review of literature.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Fibroadenoma / pathology. Fibrocystic Breast Disease / pathology. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933735.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 7
  •  go-up   go-down


96. Barrio AV, Clark BD, Goldberg JI, Hoque LW, Bernik SF, Flynn LW, Susnik B, Giri D, Polo K, Patil S, Van Zee KJ: Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol; 2007 Oct;14(10):2961-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast.
  • BACKGROUND: Phyllodes tumors (PT) are rare fibroepithelial neoplasms of the breast with unpredictable behavior.
  • All available pathology slides (90%) were rereviewed for margins, borders, fibroproliferation in the surrounding breast tissue, stromal pattern, stromal cellularity, frequency of mitoses, and necrosis.
  • RESULTS: All cases occurred in women, with a median age of 42, with 203 originally categorized as benign and 90 as malignant.
  • These patients constituted 71% of the seven patients who had uniformly aggressive pathologic features, including large tumor size (>or=7.0 cm), infiltrative borders, marked stromal overgrowth, marked stromal cellularity, high mitotic count, and necrosis.
  • CONCLUSIONS: Positive margins, fibroproliferation in the surrounding breast tissue, and necrosis are associated with a marked increase in LR rates.
  • [MeSH-major] Breast Neoplasms / pathology. Phyllodes Tumor / pathology
  • [MeSH-minor] Actuarial Analysis. Adolescent. Adult. Aged. Aged, 80 and over. Breast / pathology. Cell Division / physiology. Child. Diagnosis, Differential. Disease Progression. Female. Follow-Up Studies. Humans. Middle Aged. Mitosis / physiology. Necrosis. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562113.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Nguyen QH, Szeto E, Mansberg R, Mansberg V: Paravertebral infection (phlegmon) demonstrated by FDG dual-head coincidence imaging in a patient with multiple malignancies. Clin Nucl Med; 2005 Apr;30(4):241-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 66-year-old woman was referred for a bone scan to assess back pain on a background of breast cancer, melanoma, and rheumatic heart disease.
  • The scan appearance was suspicious for a localized soft tissue neoplasm.
  • Because FDG is not tumor-specific, accumulation in benign lesions may give rise to false-positive results despite a high pretest probability for malignancy.
  • [MeSH-minor] Aged. Back Pain / diagnosis. Back Pain / etiology. Breast Neoplasms / complications. Breast Neoplasms / radionuclide imaging. Diagnosis, Differential. Female. Gamma Cameras. Humans. Melanoma / complications. Melanoma / radionuclide imaging. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Cellulitis.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764879.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


98. Sakurai K, Enomoto K, Amano S: [Long-term results of surgical therapy for phyllodes tumor of the breast]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2784-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of surgical therapy for phyllodes tumor of the breast].
  • We report that the long-term results of surgical therapy for phyllodes tumor of the breast.
  • During ten years, we experienced twenty-eight patients of phyllodes tumors of the breast.
  • The patients with local recurrence were diagnosed the benign phyllodes tumor of the breast at the first operation.
  • If the pathological diagnosis was benign phyllodes tumor and surgical margin was negative at the first operation, it is necessary to follow up the patients, because there is a risk of local and distant metastasis.
  • [MeSH-major] Breast Neoplasms / surgery. Phyllodes Tumor / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Mastectomy / methods. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224712.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


99. Gassler N, Haferkamp A, Flechtenmacher C, Hohenfellner M, Schirmacher P, Autschbach F: [Renal oncocytoma with metastasis from breast carcinoma: a contribution to the differential diagnosis of tumourous lesions of the kidney]. Pathologe; 2006 May;27(3):217-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal oncocytoma with metastasis from breast carcinoma: a contribution to the differential diagnosis of tumourous lesions of the kidney].
  • [Transliterated title] Onkozytom der Niere mit Metastase eines Mammakarzinoms : Differenzialdiagnose tumoröser Läsionen der Niere.
  • The case of a renal oncocytoma involvement by metastasis from breast carcinoma in a 83-year-old woman is reported.
  • In conclusion, metastasis of breast carcinoma to a benign renal tumour is very rare.
  • [MeSH-major] Adenoma, Oxyphilic / secondary. Breast Neoplasms / pathology. Kidney Neoplasms / secondary. Neoplasm Metastasis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Female. Humans